ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Serine-repeat antigen protein
MKSYISLFFILCVIFNKNVIKCTGESQTGNTGGGQAGNTGGDQAGSTGGSPQGSTGASPQ
GSTGASPQGSTGASQPGSSEPSNPVSSGHSVSTVSVSQTSTSSEKQDTIQVKSALLKDYM
GLKVTGPCNENFIMFLVPHIYIDVDTEDTNIELRTTLKKTNNAISFESNSGSLEKKKYVK
LPSNGTTGEQGSSTGTVRGDTEPISDSSSSSSSSSSSSSSSSSSSSSSSSSSSESLPANG
PDSPTVKPPRNLQNICETGKNFKLVVYIKENTLILKWKVYGETKDTTENNKVDVRKYLIN
EKETPFTNILIHAYKEHNGTNLIESKNYAIGSDIPEKCDTLASNCFLSGNFNIEKCFQCA
LLVEKENKNDVCYKYLSEDIVSKFKEIKAETEDDDEDDYTEYKLTESIDNILVKMFKTNE
NNDKSELIKLEEVDDSLKLELMNYCSLLKDVDTTGTLDNYGMGNEMDIFNNLKRLLIYHS
EENINTLKNKFRNAAVCLKNVDDWIVNKRGLVLPELNYDLEYFNEHLYNDKNSPEDKDNK
GKGVVHVDTTLEKEDTLSYDNSDNMFCNKEYCNRLKDENNCISNLQVEDQGNCDTSWIFA
SKYHLETIRCMKGYEPTKISALYVANCYKGEHKDRCDEGSSPMEFLQIIEDYGFLPAESN
YPYNYVKVGEQCPKVEDHWMNLWDNGKILHNKNEPNSLDGKGYTAYESERFHDNMDAFVK
IIKTEVMNKGSVIAYIKAENVMGYEFSGKKVQNLCGDDTADHAVNIVGYGNYVNSEGEKK
SYWIVRNSWGPYWGDEGYFKVDMYGPTHCHFNFIHSVVIFNVDLPMNNKTTKKESKIYDY
YLKASPEFYHNLYFKNFNVGKKNLFSEKEDNENNKKLGNNYIIFGQDTAGSGQSGKESNT
ALESAGTSNEVSERVHVYHILKHIKDGKIRMGMRKYIDTQDVNKKHSCTRSYAFNPENYE
KCVNLCNVNWKTCEEKTSPGLCLSKLDTNNECYFCYV
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Serine-repeat antigen protein
MKSYISLFFILCVIFNKNVIKCTGESQTGNTGGGQAGNTVGDQAGSTGGSPQGSTGASQP
GSSEPSNPVSSGHSVSTVSVSQTSTSSEKQDTIQVKSALLKDYMGLKVTGPCNENFIMFL
VPHIYIDVDTEDTNIELRTTLKETNNAISFESNSGSLEKKKYVKLPSNGTTGEQGSSTGT
VRGDTEPISDSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSESLPANGPDSPTVKP
PRNLQNICETGKNFKLVVYIKENTLIIKWKVYGETKDTTENNKVDVRKYLINEKETPFTS
ILIHAYKEHNGTNLIESKNYALGSDIPEKCDTLASNCFLSGNFNIEKCFQCALLVEKENK
NDVCYKYLSEDIVSNFKEIKAETEDDDEDDYTEYKLTESIDNILVKMFKTNENNDKSELI
KLEEVDDSLKLELMNYCSLLKDVDTTGTLDNYGMGNEMDIFNNLKRLLIYHSEENINTLK
NKFRNAAVCLKNVDDWIVNKRGLVLPELNYDLEYFNEHLYNDKNSPEDKDNKGKGVVHVD
TTLEKEDTLSYDNSDNMFCNKEYCNRLKDENNCISNLQVEDQGNCDTSWIFASKYHLETI
RCMKGYEPTKISALYVANCYKGEHKDRCDEGSSPMEFLQIIEDYGFLPAESNYPYNYVKV
GEQCPKVEDHWMNLWDNGKILHNKNEPNSLDGKGYTAYESERFHDNMDAFVKIIKTEVMN
KGSVIAYIKAENVMGYEFSGKKVQNLCGDDTADHAVNIVGYGNYVNSEGEKKSYWIVRNS
WGPYWGDEGYFKVDMYGPTHCHFNFIHSVVIFNVDLPMNNKTTKKESKIYDYYLKASPEF
YHNLYFKNFNVGKKNLFSEKEDNENNKKLGNNYIIFGQDTAGSGQSGKESNTALESAGTS
NEVSERVHVYHILKHIKDGKIRMGMRKYIDTQDVNKKHSCTRSYAFNPENYEKCVNLCNV
NWKTCEEKTSPGLCLSKLDTNNECYFCYV
ENDING
ENDING
ENDING
Merozoite surface antigen 2
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMAESKPSTGAGGSAGGSA
GGSAGGSAGGSAGGSAGSGDGNGADAEGSSSTPATTTTTKTTTTTTTTNDAEASTSTSSE
NPNHKNAETNPKGKGEVQEPNQANKETQNNSNVQQDSQTKSNVPPTQDADTKSPTAQPEQ
AENSAPTAEQTESPELQSAPENKGTGQHGHMHGSRNNHPQNTSDSQKECTDGNKENCGAA
TSLLNNSSNIASINKFVVLISATLVLSFAIFI
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Serine-repeat antigen protein
MKSYISLFFILCVIFNKNVIKCTGESQTGNTGGGQAGNTVGDQAGSTGGSPQGSTGASQP
GSSEPSNPVSSGHSVSTVSVSQTSTSSEKQDTIQVKSALLKDYMGLKVTGPCNENFIMFL
VPHIYIDVDTEDTNIELRTTLKETNNAISFESNSGSLEKKKYVKLPSNGTTGEQGSSTGT
VRGDTEPISDSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSESLPANGPDSPTVKP
PRNLQNICETGKNFKLVVYIKENTLIIKWKVYGETKDTTENNKVDVRKYLINEKETPFTS
ILIHAYKEHNGTNLIESKNYALGSDIPEKCDTLASNCFLSGNFNIEKCFQCALLVEKENK
NDVCYKYLSEDIVSNFKEIKAETEDDDEDDYTEYKLTESIDNILVKMFKTNENNDKSELI
KLEEVDDSLKLELMNYCSLLKDVDTTGTLDNYGMGNEMDIFNNLKRLLIYHSEENINTLK
NKFRNAAVCLKNVDDWIVNKRGLVLPELNYDLEYFNEHLYNDKNSPEDKDNKGKGVVHVD
TTLEKEDTLSYDNSDNMFCNKEYCNRLKDENNCISNLQVEDQGNCDTSWIFASKYHLETI
RCMKGYEPTKISALYVANCYKGEHKDRCDEGSSPMEFLQIIEDYGFLPAESNYPYNYVKV
GEQCPKVEDHWMNLWDNGKILHNKNEPNSLDGKGYTAYESERFHDNMDAFVKIIKTEVMN
KGSVIAYIKAENVMGYEFSGKKVQNLCGDDTADHAVNIVGYGNYVNSEGEKKSYWIVRNS
WGPYWGDEGYFKVDMYGPTHCHFNFIHSVVIFNVDLPMNNKTTKKESKIYDYYLKASPEF
YHNLYFKNFNVGKKNLFSEKEDNENNKKLGNNYIIFGQDTAGSGQSGKESNTALESAGTS
NEVSERVHVYHILKHIKDGKIRMGMRKYIDTQDVNKKHSCTRSYAFNPENYEKCVNLCNV
NWKTCEEKTSPGLCLSKLDTNNECYFCYV
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Multidrug resistance protein
MGKEQKEKKDGNLSIKEEVEKELNKKSTAELFRKIKNEKISFFLPFKCLPAQHRKLLFIS
FVCAVLSGGTLPFFISVFGVILKNMNLGDDINPIILSLVSIGLVQFILSMISSYCMDVIT
SKILKTLKLEYLRSVFYQDGQFHDNNPGSKLRSDLDFYLEQVSSGIGTKFITIFTYASSF
LGLYIWSLIKNARLTLCITCVFPLIYVCGVICNKKVKLNKKTSLLYNNNTMSIIEEALMG
IRTVASYCGEKTILNKFNLSETFYSKYILKANFVEALHIGLINGLILVSYAFGFWYGTRI
IINSATNQYPNNDFNGASVISILLGVLISMFMLTIILPNITEYMKALEATNSLYEIINRK
PLVENNDDGETLPNIKKIEFKNVRFHYDTRKDVEIYKDLSFTLKEGKTYAFVGESGCGKS
TILKLIERLYDPTEGDIIVNDSHNLKDINLKWWRSKIGVVSQDPLLFSNSIKNNIKYSLY
SLKDLEAMENYYEENTNDTYENKNFSLISNSMTSNELLEMKKEYQTIKDSDVVDVSKKVL
IHDFVSSLPDKYDTLVGSNASKLSGGQKQRISIARAIMRNPKILILDEATSSLDNKSEYL
VQKTINNLKGNENRITIIIAHRLSTIRYANTIFVLSNRERSDNNNNNNNDDNNNNNNNNN
NKINNEGSYIIEQGTHDSLMKNKNGIYHLMINNQKISSNKSSNNGNDNGSDNKSSAYKDS
DTGNDADNMNSLSIHENENISNNRNCKNTAENEKEEKVPFFKRMFRRKKKAPNNLRIIYK
EIFSYKKDVTIIFFSILVAGGLYPVFALLYARYVSTLFDFANLEYNSNKYSIYILLIAIA
MFISETLKNYYNNKIGEKVEKTMKRRLFENILYQEMSFFDQDKNTPGVLSAHINRDVHLL
KTGLVNNIVIFSHFIMLFLVSMVMSFYFCPIVAAVLTFIYFINMRVFAVRARLTKSKEIE
KKENMSSGVFAFSSDDEMFKDPSFLIQEAFYNMHTVINYGLEDYFCNLIEKAIDYKNKGQ
KRRIIVNAALWGFSQSAQLFINSFAYWFGSFLIKRGTILVDDFMKSLFTFIFTGSYAGKL
MSLKGDSENAKLSFEKYYPLMIRKSNIDVRDDGGIRINKNLIKGKVDIKDVNFRYISRPN
VPIYKNLSFTCDSKKTTAIVGETGSGKSTFMNLLLRFYDLKNDHIILKNDMTNFQDYQNN
NNNSLVLKNVNEFSNQSGSAEDYTVFNNNGEILLDDINICDYNLRDLRNLFSIVSQEPML
FNMSIYENIKFGREDATLEDVKRVSKFAAIDEFIESLPNKYDTNVGPYGKSLSGGQKQRI
AIARALLREPKILLLDEATSSLDSNSEKLIEKTIVDIKDKADKTIITIAHRIASIKRSDK
IVVFNNPDRNGTFVQSHGTHDELLSAQDGIYKKYVKLAK
ENDING
ENDING
Serine--tRNA ligase, cytoplasmic
MHLSKIIFLLIILFPYHVNSRKPIKYKNVNNVFIEIYPCKAIKWERKKKKRDLIKNNKLI
HNVDVNYINMITNDNHISSEKCRDIKKKRKITSSEYGMSLEFFKKNPKKVVQNLKKRGME
KYLNVIVMLKKLINEKNENEVLRNKLRNRRKLLSDHIKNLIFNSKKYEDIINRDITNDSD
HKTNLIHVDEEKKKTEKKNDTQDILKDNQKIRYINKENQATNNNINNQDNSNDVLKKNKI
QIEEIKKETNQINKDIDHIEMNIINLKKKIEFNLYKLPNILLNKVPKGKTTEDNKIIKFY
KKENIIQLNNEEYDFIEPHEEIIKKYENNFIFSNISNKIGFGYNILVNDIAKLERALIDF
MINTHVNKFLYTYVKAPEIVTKSALFNTGQLPKFEEDLFKITDNYKLLNEDAYLIPTSEV
SLLNLFKNSQIDYIHLPIKLVSHSSCFRTEKNNTYGKTSKGLLREHIFQKVELINITDKK
TSPFYYKKLIKQSTYILKQLNIPYRLVLLNSIETPYSASICYDIEAWLPSQQRYVEVSSC
SNCLDFQARRLNLKYKIKDSNNFCHTINGSGLAVGRVLAIILEQYQIKKKHKNEITKIQV
PKVLRKYMNKDIIQVEYN
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Merozoite surface antigen 2
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMANEGSNTNSVGANAPNA
DTIASGSQRSTNSASTSTTNNGESQTTTPTAADTIASGSQRSTNSASTSTTNNGESQTTT
PTAADTPTATESISPSPPITTTESSKFWQCTNKTDGKGEESEKQNELNESTEEGPKAPQE
PQTAENENPAAPENKGTGQHGHMHGSRNNHPQNTSDSQKECTDGNKENCGAATSLLSNSS
NIASINKFVVLISATLVLSFAIFI
ENDING
ENDING
ENDING
Fructose-bisphosphate aldolase
MAHCTEYMNAPKKLPADVAEELATTAQKLVQAGKGILAADESTQTIKKRFDNIKLENTIE
NRASYRDLLFGTKGLGKFISGAILFEETLFQKNEAGVPMVNLLHNENIIPGIKVDKGLVN
IPCTDEEKSTQGLDGLAERCKEYYKAGARFAKWRTVLVIDTAKGKPTDLSIHETAWGLAR
YASICQQNRLVPIVEPEILADGPHSIEVCAVVTQKVLSCVFKALQENGVLLEGALLKPNM
VTAGYECTAKTTTQDVGFLTVRTLRRTVPPALPGVVFLSGGQSEEEASVNLNSINALGPH
PWALTFSYGRALQASVLNTWQGKKENVAKAREVLLQRAEANSLATYGKYKGGAGGENAGA
SLYEKKYVY
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Probable ATP-dependent helicase PF08_0048
MNEIKSESLLQTRPFKLGIEDIQNLGSSYFIENNEKLKKYNNEISSLKKELDILNEKMGK
CTTTTKIVEPAKTPEFTFWYYELKEMKGFQDLVMYEVKKKKKHFKVLSHSCLKYLSNREK
MKIKKQEEEEKRLKLYSKNISSYMDVFWKKIEKLVWEEKKRELQQTLNKKKEMRFKKFVK
EAIKKIKDARHNNAHELFENKYVSMSSNNNSEIVNNNASSVDNGDKELKEDDLTDQEEED
YLLDEQMSSTDESENKEEEINMLDDEANLPIEELLKRMYGFKSGEDYINFMENEDDANEE
NVIETSHNDEKSGDNSIGEDDNNNDEKGGDNNIDEDDNNNDEKSGDNSIGEDDNNNDHKS
GDNNIDEDDNNNDHKSEDNSIGEDDNNNDEKGGDNNIDENDNNSDHKSEDNNIDENDNNS
DHQSDQEQFNHETKDDIIKNSSYEHIDNKNYYNKTGEDYKSDKENYSPTRFHNKLKKEKY
DEYDTKLKIEKREEENKNYEKDEHEYESDNYDKEKINKKKELILLKNDIENDSDETSEHI
KRDSRSSCQKQNCEKKRRIIKDEYNLRRTKIAKSKPSSDNNNSENDNNNDNNNDNNNDNN
DDNNDDNNDDNNDDNNDDNNDDNNDDNNNEHKNDSDDNDDILTCNMDEKHLTKIPPIIKA
TLRDYQHAGLHWLLYLYKNNINGILADEMGLGKTLQCISLLSYLAYYFNIWGPHLVIVPT
SILINWEIELKRFCPCFKILSYYGNQNERYKKRVGWFNKDSFHICISSYSTVVKDHLVFK
RKRWKYIILDEAHNIKNFNTKRWNIILSLKRDNCLLITGTPLQNSLEELWSLLHFLMPNI
FTSHLDFKEWFSDPLNLAIEKSKIHHSKELIDRLHTVIRPYILRRLKKNVEKEMPNKYEH
IIKCKLTRRQQILYDEFINNKNVQNTLNTGNYIGLMNILIQLRKVCNHCDLFTNKYIQTP
YYYMLSIRYFVPRFFILFEKNYYADFYLILFLHNEFTSLGGRDVTKETSPSSKSFDLAHI
LTKHNTNELYDNNHISELYDNNHISELYDNNHISELYDNNHISELYDNPMSHKNYKHNSN
GYTYPNDPINNMNNNPSGFTKTSEQFGQIVSHERDNNYHMMDHNNMNNLLSKEMVNSLRN
DDNSNNNFYKYSLTSNNNDSQTSIHDNKQCDYNKLCADTFNNINSIGNEEKRSLNVLNEQ
NNNNSKDNNNNIDNNNNIDNNNNIDNNNNIDNNNNIDNNNNNIDNNNNIDNHHNNNQHCN
YNDNWPSDYPTNIINHRNAFLSILKLLNQSNPLNNDNNNNNNNNNGNNNIYNMNRYNSRN
SRNSSLSNIFSSNTSKMNSFQLDFLYTNSFINQDALCKNSFFVNINIEDVHSYIYNSIYK
EYIPKNILSFSDEFLTELNNNYDILSLYIDPYNRYKSYNEYLYKMKEEGTLTNQQSLGDI
NNKHIYHKSTSNENTHMKNRKTFIYKYNNMFKVINNDTQYQNIFTDDTNNSYYNSLEHNL
WIKRNQIDERKKEEEEEQNKYYNVCMNNLYILRNERIPIFGKNFLDLIKKEFTKDKNIVY
NYTNNVPIDYYSSVKEVWVEDICEKDNKKRKCKREKRWYKKIKKTNNPPEDSEVYRENSS
DVEKYNCDVEKDNCDDEEKDNCDDEDMNSNLSSNVYGCIDISSQNFIHSRYHNPMMNMSY
IIEFLFPNMEQFLKRHEKMIHNFTLINNPSVICKSHDIRINNNLLNYSNDKMNPIILQIK
NATRVYHDAFLKQSIIFPLNKDISLGSGKLCALEKLLSKCKREGNKCLLFTQFIKMLDIL
EIFLNHLNYSFIRLDGSTKVEQRQKIVTKFNNDKSIFIFISSTRSGSIGINLTAANVVIF
YDTDWNPSIDKQAMDRCHRIGQTKDVHVFRFVCEYTVEENIWKKQLQKRKLDNICINMGN
FNNSNTHSKITDTDPTHNKDWFTNVDTIKEVFINKKNNDDDDDMYKDRLLHEQVENKDKM
NVRFEKTLEHVEDKDDIRALNETKKETQNEISQNMQEFTTRNDFQDSYNLTSYCFNFLNE
NLTDSLKQQIDEMRMKIEIEMMNTGDENMSLSDLSNKSHNSE
ENDING
ENDING
ENDING
ENDING
Merozoite surface protein 1
MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYSLFQKEKMVLNEGTSGT
AVTTSTPGSKGSVASGGSGGSVASGGSVASGGSVASGGSVASGGSGNSRRTNPSDNSSDS
DAKSYADLKHRVRNYLLTIKELKYPQLFDLTNHMLTLCDNIHGFKYLIDGYEEINELLYK
LNFYFDLLRAKLNDVCANDYCQIPFNLKIRANELDVLKKLVFGYRKPLDNIKDNVGKMED
YIKKNKKTIENINELIEESKKTIDKNKNATKEEEKKKLYQAQYDLSIYNKQLEEAHNLIS
VLEKRIDTLKKNENIKELLDKINEIKNPPPANSGNTPNTLLDKNKKIEEHEKEIKEIAKT
IKFNIDSLFTDPLELEYYLREKNKNIDISAKVETKESTEPNEYPNGVTYPLSYNDINNAL
NELNSFGDLINPFDYTKEPSKNIYTDNERKKFINEIKEKIKIEKKKIESDKKSYEDRSKS
LNDITKEYEKLLNEIYDSKFNNNIDLTNFEKMMGKRYSYKVEKLTHHNTFASYENSKHNL
EKLTKALKYMEDYSLRNIVVEKELKYYKNLISKIENEIETLVENIKKDEEQLFEKKITKD
ENKPDEKILEVSDIVKVQVQKVLLMNKIDELKKTQLILKNVELKHNIHVPNSYKQENKQE
PYYLIVLKKEIDKLKVFMPKVESLINEEKKNIKTEGQSDNSEPSTEGEITGQATTKPGQQ
AGSALEGDSVQAQAQEQKQAQPPVPVPVPEAKAQVPTPPAPVNNKTENVSKLDYLEKLYE
FLNTSYICHKYILVSHSTMNEKILKQYKITKEEESKLSSCDPLDLLFNIQNNIPVMYSMF
DSLNNSLSQLFMEIYEKEMVCNLYKLKDNDKIKNLLEEAKKVSTSVKTLSSSSMQPLSLT
PQDKPEVSANDDTSHSTNLNNSLKLFENILSLGKNKNIYQELIGQKSSENFYEKILKDSD
TFYNESFTNFVKSKADDINSLNDESKRKKLEEDINKLKKTLQLSFDLYNKYKLKLERLFD
KKKTVGKYKMQIKKLTLLKEQLESKLNSLNNPKHVLQNFSVFFNKKKEAEIAETENTLEN
TKILLKHYKGLVKYYNGESSPLKTLSEESIQTEDNYASLENFKVLSKLEGKLKDNLNLEK
KKLSYLSSGLHHLIAELKEVIKNKNYTGNSPSENNTDVNNALESYKKFLPEGTDVATVVS
ESGSDTLEQSQPKKPASTHVGAESNTITTSQNVDDEVDDVIIVPIFGESEEDYDDLGQVV
TGEAVTPSVIDNILSKIENEYEVLYLKPLAGVYRSLKKQLENNVMTFNVNVKDILNSRFN
KRENFKNVLESDLIPYKDLTSSNYVVKDPYKFLNKEKRDKFLSSYNYIKDSIDTDINFAN
DVLGYYKILSEKYKSDLDSIKKYINDKQGENEKYLPFLNNIETLYKTVNDKIDLFVIHLE
AKVLNYTYEKSNVEVKIKELNYLKTIQDKLADFKKNNNFVGIADLSTDYNHNNLLTKFLS
TGMVFENLAKTVLSNLLDGNLQGMLNISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYK
QEGDKCVENPNPTCNENNGGCDADAKCTEEDSGSNGKKITCECTKPDSYPLFDGIFCSSS
NFLGISFLLILMLILYSFI
ENDING
ENDING
Fructose-bisphosphate aldolase
MAHCTEYMNAPKKLPADVAEELATTAQKLVQAGKGILAADESTQTIKKRFDNIKLENTIE
NRASYRDLLFGTKGLGKFISGAILFEETLFQKNEAGVPMVNLLHNENIIPGIKVDKGLVN
IPCTDEEKSTQGLDGLAERCKEYYKAGARFAKWRTVLVIDTAKGKPTDLSIHETAWGLAR
YASICQQNRLVPIVEPEILADGPHSIEVCAVVTQKVLSCVFKALQENGVLLEGALLKPNM
VTAGYECTAKTTTQDVGFLTVRTLRRTVPPALPGVVFLSGGQSEEEASVNLNSINALGPH
PWALTFSYGRALQASVLNTWQGKKENVAKAREVLLQRAEANSLATYGKYKGGAGGENAGA
SLYEKKYVY
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Apical membrane antigen 1
MRKLYCVLLLSAFEFTYMINFGRGQNYWEHPYQKSDVYHPINEHREHPKEYQYPLHQEHT
YQQEDSGEDENTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIE
EVHGSGIRVDLGEDAEVAGTQYRLPSGKCPVFGKGIIIENSNTTFLTPVATGNQYLKDGG
FAFPPTEPLMSPMTLDEMRHFYKDNKYVKNLDELTLCSRHAGNMIPDNDKNSNYKYPAVY
DDKDKKCHILYIAAQENNGPRYCNKDESKRNSMFCFRPAKDISFQNYTYLSKNVVDNWEK
VCPRKNLQNAKFGLWVDGNCEDIPHVNEFSAIDLFECNKLVFELSASDQPKQYEQHLTDY
EKIKEGFKNKNASMIKSAFLPTGAFKADRYKSHGKGYNWGNYNTETQKCEIFNVKPTCLI
NNSSYIATTALSHPIEVEHNFPCSLYKNEIMKEIERESKRIKLNDNDDEGNKKIIAPRIF
ISDDKDSLKCPCDPEIVSNSTCNFFVCKCVERRAEVTSNNEVVVKEEYKDEYADIPEHKP
TYDKMKIIIASSAAVAVLATILMVYLYKRKGNAEKYDKMDEPQHYGKSNSRNDEMLDPEA
SFWGEEKRASHTTPVLMEKPYY
ENDING
ENDING
ENDING
ENDING
Merozoite surface antigen 2
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMANEGSNTNSVGANAPNA
DTIASGSQRSTNSASTSTTNNGESQTTTPTAADTIASGSQRSTNSASTSTTNNGESQTTT
PTAADTPTTTESNSPSPPITTTESSKFWQCTNKTDGKGEESEKQNELNESTEEGPKAPQE
PQTAENENPAAPENKGTGQHGHMHGSRNNHPQNTSDSQKECTDGNKENCGAATSLLNNSS
NIASINKFVVLISATLVLSFAIFI
ENDING
ENDING
ENDING
Merozoite surface antigen 2
MKVIKTLSIINFFIFVTFNIKNGSKYSNTFINNAYNMSIRRSMANEGSNTKSVGANAPKA
DTIASGSQSSTNSASTSTTNNGESQTTTPTAADTPTATESNSRSPPITTTESNSRSPPIT
TTESNSRSPPITTTESNSRSPPITTTESNSRSPPITTTESSSSGNAPNKTDGKGEESEKQ
NELNESTEEGPKAPQEPQTAENENPAAPENKGTGQHGHMHGSRNNHPQNTSDSQKECTDG
NKENCGAATSLLNNSSNIASINKFVVLISATLVLSFAIFI
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Merozoite surface antigen 2
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMEESKPPTGAVAGSGAGA
GSGAGAVAGSGAGAVAGSGAGAVAGSGAGAVAGSGAGAVAGSGAGAVAGSGAGNGANPGA
DAERSPSTPATTTTTTTTNDAEASTSTSSENRNHNNAETNPKGKGEVQKPNQANKETQNN
SNVQQDSQTKSNVPRTQDADTKSPTAQPEQAENSAPTAEQTESPELQSAPENKGTGQHGH
MHGSRNNHPQNTSDSQKECTDGNKENCGAATSLLNNSSNIASINKFVVLISATLVLSFAI
FI
ENDING
Merozoite surface protein 1
MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYSLFHKEKMILNEEEITT
KGASAQSGTSGTSGTSGPSGPSGTSPSSRSNTLPRSNTSSGASPPADASDSDAKSYADLK
HRVRNYLLTIKELKYPQLFDLTNHMLTLCDNIHGFKYLIDGYEEINELLYKLNFYFDLLR
AKLNDVCANDYCQIPFNLKIRANELDVLKKLVFGYRKPLDNIKDNVGKMEDYIKKNKKTI
ENINELIEESKKTIDKNKNATKEEEKKKLYQAQYDLSIYNKQLEEAHNLISVLEKRIDTL
KKNENIKELLDKINEIKNPPPANSGNTPNTLLDKNKKIEEHEKEIKEIAKTIKFNIDSLF
TDPLELEYYLREKNKNIDISAKVETKESTEPNEYPNGVTYPLSYNDINNALNELNSFGDL
INPFDYTKEPSKNIYTDNERKKFINEIKEKIKIEKKKIESDKKSYEDRSKSLNDITKEYE
KLLNEIYDSKFNNNIDLTNFEKMMGKRYSYKVEKLTHHNTFASYENSKHNLEKLTKALKY
MEDYSLRNIVVEKELKYYKNLISKIENEIETLVENIKKDEEQLFEKKITKDENKPDEKIL
EVSDIVKVQVQKVLLMNKIDELKKTQLILKNVELKHNIHVPNSYKQENKQEPYYLIVLKK
EIDKLKVFMPKVESLINEEKKNIKTEGQSDNSEPSTEGEITGQATTKPGQQAGSALEGDS
VQAQAQEQKQAQPPVPVPVPEAKAQVPTPPAPVNNKTENVSKLDYLEKLYEFLNTSYICH
KYILVSHSTMNEKILKQYKITKEEESKLSSCDPLDLLFNIQNNIPVMYSMFDSLNNSLSQ
LFMEIYEKEMVCNLYKLKDNDKIKNLLEEAKKVSTSVKTLSSSSMQPLSLTPQDKPEVSA
NDDTSHSTNLNNSLKLFENILSLGKNKNIYQELIGQKSSENFYEKILKDSDTFYNESFTN
FVKSKADDINSLNDESKRKKLEEDINKLKKTLQLSFDLYNKYKLKLERLFDKKKTVGKYK
MQIKKLTLLKEQLESKLNSLNNPKHVLQNFSVFFNKKKEAEIAETENTLENTKILLKHYK
GLVKYYNGESSPLKTLSEESIQTEDNYASLENFKVLSKLEGKLKDNLNLEKKKLSYLSSG
LHHLIAELKEVIKNKNYTGNSPSENNTDVNNALESYKKFLPEGTDVATVVSESGSDTLEQ
SQPKKPASTHVGAESNTITTSQNVDDEVDDVIIVPIFGESEEDYDDLGQVVTGEAVTPSV
IDNILSKIENEYEVLYLKPLAGVYRSLKKQLENNVMTFNVNVKDILNSRFNKRENFKNVL
ESDLIPYKDLTSSNYVVKDPYKFLNKEKRDKFLSSYNYIKDSIDTDINFANDVLGYYKIL
SEKYKSDLDSIKKYINDKQGENEKYLPFLNNIETLYKTVNDKIDLFVIHLEAKVLNYTYE
KSNVEVKIKELNYLKTIQDKLADFKKNNNFVGIADLSTDYNHNNLLTKFLSTGMVFENLA
KTVLSNLLDGNLQGMLNISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVEN
PNPTCNENNGGCDADAKCTEEDSGSNGKKITCECTKPDSYPLFDGIFCSSSNFLGISFLL
ILMLILYSFI
ENDING
Merozoite surface antigen 2
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMEESKPPTGAVAGSGAGA
GSGAGAVAGSGAGAVAGSGAGAVAGSGAGAVAGSGAGAVAGSGAVAGSGAGNGANPGADA
ERGPSTPATTTTTTTTNDAEASTSTSSENRNHNNAETNPKGKGEVQKPNQANKETQNNSN
VQQDSQTKSNVPRTQDADTKSPTAQPEQAENSAPTAEQTESPELQSAPENKGTGQHGHMH
GSRNNHPQNTSDSQKECTDGNKENCGAATSLLNNSSNIASINKFVVLISATLVLSFAIFI
ENDING
Merozoite surface antigen 2
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMAESKPPTGTGASGSAGS
GAGASGSAGSGDGAVASARNGANPGADAEGSSSTPATTTTTTTTTTTTTTNDAEASTSTS
SENPNHNNAETNPKGKGEVQKSNQANKETQNNSNVQQDSQTKSNVPPTQDADTKSPTAQP
EQAENSAPTAEQTESPELQSAPENKGTGQHGHMHGSRNNHPQNTSDSQKECTDGNKENCG
AVTSLLSNSSNIASINKFVVLISAKLVLSFAIFI
ENDING
Merozoite surface antigen 2
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMEESKPPTGAVAGSGAGA
GSGAGAVAGSGAGAVAGSGAGAVAGSGAGAVAGSGAGAVAGSGAVAGSGAGNGANPGADA
ERSPSTPATTTTTTTTNDAEASTSTSSENRNHNNAETNPKGKGEVQKPNQANKETQNNSN
VQQDSQTKSNVPRTQDADTKSPTAQPEQAENSAPTAEQTESPELQSAPENKGTGQHGHMH
GSRNNHPQNTSDSQKECTDGNKENCGAATSLLNNSSNIASINKFVVLISATLVLSFAIFI
ENDING
Merozoite surface antigen 2
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMTESKTPTPTGAGAGASG
SAGSGDGASGSASGSASGSASGSAGASGSASGSAGASGSASGSAGAEGSPSTPATTTTTT
TTNDAEASTSTSSENPNHNNAKTNPKGNGGVQKPNQANKETQNNSNVQQDSQTKSNVPPT
QDADTKSPTAQPEQAENSAPTAEQTESPELQSAPENKGTGQHGHMHGSRNNHPQNTSDSQ
KECTDGNKENCGAATSLLNNSSNIASINKFVVLISATLVLSFAIFI
ENDING
Merozoite surface antigen 2
MKVIKTLSIINFFIFVTFNIKNESKYSNTFINNAYNMSIRRSMAESKPPTGDGAVASAGN
GAVASAGNGAVASAGNGAVASAGNGAGNGAGNGAGNGAGNGAGNGAGNGAGNGAGNGAGN
GAGNGAGNGAGNGAGNGAGNGAGNGAVASAGNGAGNGAVASAGNGAVAERSSSTPATTTT
TTTTNDAEASTSTSSENSNHNNAETNPKGNGEVQPNQANKETQNNSNVQQDSQTKSNVPR
TQDADTKSPTAQPEQAENSAPTAEQTESPELQSAPENKGTGQHGHMHGSRNNHPQNTSDS
QKECTDGNKENCGAATSLLNNSSNIASINKFVVLISATLVLSFAIFI
ENDING
ENDING
ENDING
ENDING
S-antigen protein
MNRILSVTLCLFFIYLYIYKTYGKVKNTDEGLSNIYGAKYYLRSGLFNEKNGKGQKYEDL
EEEKEGENDDEEDSNSEESNNDEENELIKGQEGVEQETHGSEDEVSNGREDKVSNGGEDE
VSNGGEDEVSNGREDKVSNGGEDEVSNGREDKVSNGGEDEVSNGREDKVSNGGEDEVSNG
REDKVSNGGEDEVSNGREDKVSNGREDKVSNGGEDEVSNGREDKVSNGREDKVSNGGEDE
VSNGREDKVSNGGEDEVSNGREDKVSNGGEDEVSNGREDKVSNGREDEVSNGREDKVSNG
GEDEVSNGREDKVSNGGEDEVSNGREDKVSNGREDKVSNGGEDEVSNGREDKVSNGGEDE
VSNGREDKVSNGREDKVSNGREDEVSNGREDKVSNGGEDEVSNGREDKVSNGREDKVSNG
GEDEVSNGREDKVSNGGEDEVSNGREDKVSNGREDKVSNGREDKVSNGGEDEVSNGGEDE
VSNGREDKVSNGGEDEVSNGREDKVSNGGEDEVSNGREDKVSNGGEDEVSNGREDKVSNG
REDEVSNGREDKGGAGTDGELSHNSESHTKNKKSKNSIINMLIGM
ENDING
ENDING
Putative E3 ubiquitin-protein ligase protein PFF1365c
MKDLYSLYEDISENDKIIISEKLKNLLNYFQDKNKSYVSEFVVVSRTRFFKSISNYGEFL
LLQSSSRVISSYEHILRLLHQAKVYLEFVRCLKLNNCSVIDNEKYEEEISKFINYLESKR
KKYYYHICQILIKFIVSSLSDNTIDNKFMEKEFDIEEDNIDGYEKNVNDIEIKNEEYNTS
YESQRVKDNNNSNYNNNVNIWTINDNDEKIVMEPFDELEEYGNYLYNVLNQMDNKSWKDK
NHAEYLKVISLNDAIIKEDNDKNKNSENNNGLTNTSNITNNMILLPKYLENVRNCIYNHQ
TKSMLEVKSMIEHAMSDNIKAPLFKTGKIVSEMLPSPNYEKYWSTTQPEFSNKIDTSLVQ
NMIFKFFNLQKNTTPVDNMTPTNYNIKFYDIFKIILKGIYSIKCENEETHIFLNQLLNKT
KKKKYPFNYNNQLLDKNVKTDDLYNYLLLPLHLYNNTHEICEGILKYTIYNNDLVLTLKI
VDTFLTISVYENSLKDLVHLLNTLAECIILPYLRTEIKENIKHDTGDKDIYRTGTLCKNF
ETELTNEFNKISDDNNNNNNIGIIDTNKSRDNINQNTNTNNNNNNNNNNDGDRFDDDQFF
DNFSNLHKLICKIPLHEYESLKLLELFSLQYPMFLKIQNKPQRCLKDISKPCEYYSNTLP
IYGSYIFQIVVSFEIDNSIKVLDELGSKCKICFQLTNDNMNDENSTDITVSDDNSNIPNK
EYNFLEINFQQNHMYTKYNKSSVKEEDEIEKSMKAKSSTKSNDETNKANNNKNNNNNNKN
NNNNNKNNNNNNKNNNNNNKNSNNNNNNNNDTFEEYEKNNKKKKKNVQVNKLINVYDITN
MNTIVFDILIDQGCFSSETNVNNVTNDNGKIVIYSNGRHLLTSNINKKIIGFNEKKGLTN
NNIKLKVFTSRTCSFEFPKECYWSSAFVQELVNRKLIPETNQNFLLKNPINIIELYNKVS
IALNRYLYRFCEWNNGDYKRIIENDSCYTLYNNIDINTFEALIKYTENNNKILKKLYTLS
KNCALDKENYMENNKHNINYYFSLSPVKYHVRKYREYIYEWNQTSDSQICALSILKLYLK
NNLDVNDGRIEHNEKFYCLSERLIKSFLKIIKLKTPFINREDFYVNNNYEMEELDLDGSL
WLLRRNVFQILLDADKIIMSNIFMRINIETILNLLKFFSDNNSLDSDMILKLLKSLEEKG
ILEIMMKRMLSTPCKDGTQYNNSNYNDNSHYTHNSLKSQNISSSTYSSSSSSSNLYNTNA
ENFNDIYTNNNGEEKRKKRKYYEENMHEIQRYEKRKRNNKSRIIDTTHFGVFVEELMTLI
EHQTNNAINTPVVNHIEESDVFMENKACDVIHKLCSFYNDEIKSEVFLRNYNHFNLCIKI
LNEIKKKNNHVSSASEVASIFLRGVVLMLTTYILTIATEYESTKTFLYKPVIPFYNLHNE
MLKKKKDIHVYHGEEIKQMISMNSKSMKDRYNNQFNQYGSNNKSSNLTNQNIDILKCDME
DVSSCNSRYSSFINQNWELEYNKKIKKNNSISNNEYNKKGDVESRDHANSWIPLISNQND
GSIDGVIIHSDDSSSQSFLVSKRKVYTFGRKSFESVNMYVDDNEEDEGEEDKSEDYEYCD
DEQQNDVYEDTEEESDNYHMRKERRVHQKKKNSKVSINKKTNNSLSDDNNYSSDELEEFY
LRKNLLDLCDNNNNNNNNDEPNNFKSQLNEILYKLSKKKKYARNSKKLKLLKKKIIKYKN
VSKKLNFIFSLLEEILKIMLSVGLRVLSSISYHYLYEKNGIYKFINIFGSNIIRSNLRDK
GSFLELCENMIKPKCLTLLQACTFIISGIIPCLGYVTTLFVDKKANKYFYIKELNNYLSL
KMALNIWPMFLKITLQGLLTSRHLSSEMSVHKDNLHPIAECCISITSLATHFLTLFTIMI
DNLSRYEIYFNLKKGMNTLGNNYPIPLILINSAKYIRIESKKNKYYDIEKAIRTILLQLT
DCSVCDYENYVFNHYMVPQSISSFLYATRMNNDSNLENEHSSNNINAHETDYHDISINKN
KALGNEMVKTYQSMYEDDYEQERIGIRSRSRRGIPLKKKSERNNSKEENVNNMDHNNNNN
SNSNNNNFFHRGSYSTNPRNNNITCDRKNMEFLKKLMKNDHDAVQCLGKAYSVFHKNFER
AQIAFVAVFLHLTGYKHGQIKGPHQNYNSAKNNNDNKNDHIIIEDSLENKKIKIACNLAR
QGVIDLISKSQASQYHKKSIEEYNTSSKNKKCKEEIQEQMSMEHFEGNNKRMNNVKSGSH
NDFKNLVRESHQNINEIDPDDNNKSNVYSSIEQVNDLPLNKKKSPILHLSSDLDEKNDLN
FCNFSKEELNYVNDVHPNGEKSSHNNKSNEFLAMDSIQKKREKQIEKILQKCEWIINTYP
FGLCPVSVKENISQEWDEHFVFMRRNSYDIPITVRKMYSDRSNYQMLHEVATMPAVAVEP
SVSSLSYLDQLFSHQNKINDDKLECIQFSTENIFGKSTTKNLFLLKKLLKTYKRNVCIRE
PSNQLDTNKYDKICLENNKQFHTYICNNKNVNFSNSCASCDSGEGNYYNDESNYYMNFHF
SEKNNDHLSNNSLVLKYNNLCKTNNLEKFGELWLNARSTKNYVYHNDQDVQHIDEFNSNL
MNYKPECFLFSLKSVDENDYIMRNENMNNVKWDPTGSHITKYTNSMFDYYDNASDMNLSE
LHGKFNAFYKPQKIIRSMNKQEFLPALYQEEMLRNQPYHTTANNNTTNIINTTKKKSFPS
FDYFRNKYLPNNSIDFTINNAVDHTIDSKDMLQLKEILKFIMNDTDLETVLNIIRIEQLT
SLCRYLISRSLKSMLCAGIFGGIKNPIVNMSKKNLSSNKRSQKGYNSNSDDIKKKKKSNC
NENEGSLDKYNDKEKKNDKINNGDTKNSDDGKIDMDDKKYYNDDLKNSDYSKNNESNYLS
LSKEPDDMLLPSPNYEKGISTCVKKNRFSVLSEAYKEENLLVNQRKYKNLDLNQKIFKND
KRKKGIFEQWRQKSTKSMQWPVILDLLVPSFSRGSYNECNRMISNMESSLFSVQNYGWML
LKLLHIIIIKFRSLTPLKTIMREIDEKNRNSNNNNNNNNTNNSNNSNNNNNINSHYMNQW
NGSNIKDPFEYHYWFTQPMEYALSFTLTDITKSICIWYLRYNRKLIMNSSSFSEIIKNSM
NTLWIESVLRLIALQICLGVKPLNDSRYVVPFLYHMFTICQPLLREVHISGDYLKKKLLV
GNKILYYSNKNNSFLQVKCSYCHKSVCMSSRKMSSKMSPMETPLKSIRKGNSSEVSSKIS
YLNGHTYSNNDNRDNYDDDNCDNYDNYDNDNENDNCDNSKNDRGVKGYIHSERVQKKQKK
IKHKIIKMKMYNLSEQEHEEILDNVITGIIIYHQTLQNNNQHINKMIILQNLKGFKIKEE
YYTNENHYWALCVQQYKNSPLYTLPLKNLNKCIKHNNRNIFQTTKMNESDDTSCYYWSVS
GDPVYNIYGNAKSISDVQLEICAHKKYDSNVRSYLKKNNFELEFSINTHMNDVVNIWIKR
KSIIINKELIEITDHHSIPLFSKGKQKKEMQENEDEKIKNKGKNKTKTNDDKKKNSSINN
NNDCYDINYKYDTYNHEENDGSHKEENKKYSNENENVEYLSEHFCDCMKVYTDQDYSNED
YSNDYNYNCDNYKNMYSDDKKNRDLYDHGDNNLNYKKLKLISWNLIQTILWGILVSGENV
QMENSDQVISESTTKYIKKKICNIQDEIDVNGNNHNDYKDYKYAFYKLQRKSLIESVLKM
IMSVLIKLCNIVKLYNDLTKNKKGSFYICINNTKISMKQVKDCERMITDFMYALIKCVQN
SSTAAVTLLRCFLFGQDNPTYRFRKLNKIQINCKFYRLITECIKKAPSDADDISIFFNTY
LDKKKTLMNNDNDKINTKTTKKTKKEKTTKCYKNEMYDEKATMENNKKNNMGDLKWNEGE
APAHPSKDKSKHYNDNNNNNNDDNNSNNNNDYNNKDHINYPDDYVYNNRCIKYKGMDLKM
SNFFFKYYDTNMKKNYNESKIHGFFLLRCLPPIKMFPKQLVIQETQKLFQNENNFLFNSK
KDGSSNNDKNDNSNKNRNNYNNNDDNNNNDDNNNNNDDNDDNDNINNNYNNNNNNNNRNN
SNSNNSNNSDNNNINYYYNNTDYQIGEHNNMQIHSSSKENTLYPDDHQNVDISTTTNEGN
SQCNSINNILGLIPRISYRNHPFDDLPQSEFFMSSRPSDDFEAHMEGRVLRVLRGLNLGG
VVLCLAPLTFPALHVGPNEVNDIINFRIQTRGRFGVTVAPAECVLSNVSEVFDRNDVVGF
RTNMCPPFRHDVFAANVQYELGDLLSVKFNVEDQQNQKCLRTELMVSGVSIGSVLEVLFE
ADSQIEFERRMNLIFIFQDPLTIVYEGPTFTMQYVDPNKNNANNFRNDKKNADEEFLNEL
YSLSGYDKKNFKKELRKIRMKKNEFYESVKLYQSILESDNEILKDLKHEVIIRMNTSLTN
IVSYFKHLSSNGVIFNSENDYYYWNDTDDTLLRKITTKKKKKHLYNMNCNNKMNEKYELI
SLDTLLSNDEKKKKMNNMNILNNPNFKTKGGKKKKKINIHLSNDKEEDKDEEAKYVEGIK
QEKHTYYDYSNNSLLYNENKDNSVDNYYSFGNKEDGNRDIFSYSEEKHYNIITYDNSQIT
SSDKNNDPNREKILEKKNFQDDSIMSNRQSDNKEEGTSFNLYADSSIYVNMNKKYKSHVD
IHKTIREVLSIICVLGLNINGEPKENKQEKFSNDTNYIFDELPWLTSLSDLKNSVTYNLD
RKCLELFFCNLVDIICMDVFLGSILNFVTHNINENNQRCTRDKHNIVSFKHNKNYKKVIQ
KTSELDSECYPNEEYNDEFFENRKGSPYFPSRSKNGNINSDRRKNYNIQNSDNSNIGDSE
LNVNVNDNDNSSCGSNSKDSLNVHARNVGTDINSSSESGNTNSNNENSLRNSIFMEENET
IESYRNKTKRSLSKDKNAGDLSNDNTEEIYHNNRYKKEKNKDEKNKIKKNKSYKNKTHKN
KKQKNKSSNADKMNKNSLYGYTLCLIGTKSIMCCCIILRTLLEMNSDGYYEPNEKMYASC
KRLLNFIKLFFFIDIGISDVLIKYFAEKNKMMDMNFLFDKRKQTQNGNNNSEICSTSSFL
NSFVKNTNGNNKKKNNNHNDNHMDCMNWKEEVVFYNQKYHDNMHTKDLLNNKEDNQSSYI
STNGKNKDTKDAVQNEYINILEIVNYCGIPNNFLEYFDISTPTIKNQQVIAQNDSFDLWI
YIMNLLICFNSQNKYSLSFPQSINQLSENSIKNTLFDLEYSKFYFSNKILRKSVKFYASW
LLKKYIIDMTCVMASLVPKLFIDELKTNLMKINEGVRSGEEIENMRNVQNKYTNSQDSVN
YSSANTKEMNHKTIVPKCCFENEKTKLDHVVNNKEGHQMGFDSFNDKKDGLHNIHHAKSC
EEKNNTKSNSYNNYNNYDNYNNINKYSCYNDKEEYQHELLCINNDYTHHNKTQGNFNDKL
MHAKKKYNSKYRKVNKVEHIGQLLNAHLRNKEEILNIFSIMYLFRICIYYLGRSKDFRKE
DYWQNFQGQLRNAKIKENVYKLLNEKSCKSSLLFGWQRIFYQCVVSWDDEKLVDQLLIII
QSELLYHLIGSVAQSMSQKRVKVEQFYAISPSVHVAHWMIDTFVRHPLCPSKIRSCCITP
MTVTSLFGLIMNGNRLPIFLGIDVCRLVYWCCVVYILQNNQMHKHYKKLNNIDILTQLNI
TMEEPLNNDLEYTTCANQKKMITKNYHNTKSNKQHNNYFSTRGKMQKVKCNYYSFLSYVF
HCVNICGSSVINQIISFNNNDVGYKNNVNKNKGNDNVSNNNNNNNNNININSSSNNNNNN
SSSNNNNNNSSNNNNNSSNNNNNSSSSNNNNVRNSNNEHVNNIIDNLNNNINDILNCIQN
SSNNRVLNNHFSGISSVSNETIYNLNITNRRNSHNISSNNINNTNTLQENTETNNTSNVN
NLGGINSLYVNGTNGNLKTDKILLHNFSNFDLMENKEPSMYNSMKMNASLLVHYFACAAY
YIKRADVYNIMNYYNEHTHANFKQYCLYLYVVDHVSKIYSKHIKRKINLKKKGGKKDDQL
MTSSFFSDLMKKDPNEKSHMCYDDYTNNKYDNNNNKNNLVNNENELIVRKDSKISSKNYS
FNSDYKHADKTKCRKHTYDESYKGQYPELFVDDVLHIPKKLSANIIINMNEKIHHISSSN
SNTIKIKIRDMFVLPKQNDKSFIHKGIFSTHHNKPFYDKEDKYMFGEKNIVEHKNKQKQL
YADHSNHQNKKHFTYNENKDKFNDKSNCNLKQKINRLNSEENERIEKINQKNFKHPNIIF
SADNSFNYILHEIKFKKIQEFVYLNSNVIDEKVDLDTIEKITLGSYIELTDIYNLPGSFF
LIGNSELYSGSSNLCSSSFTISLILVDNNADNMSDGNFNNFPNIEIGVINRKKYFEIKLE
EDQNEDEDKIEIEIEEEKENENEKEVEKDENVHDEKDKVEQIEHEKKKEKDDKEAWLLHY
DDGKDTNVKVKKFSNCRISKNEEDNIAYRLRNKELLGEKNITSKNSKFLYDKNVVDESLK
CTRKNEDEYEGTEKRHSSNIPTDINKIAHVSLTKYINNEKIEKSKTRGGKRVQNVVEKLR
NTLNDNNIKEDILNENHNKNNININSNINSNNNMMRGKMFHENLCDINMKNLGSNFYHSK
YADLNKTNYITLNISDGNVNSKGFDCTDNNIENMKELLTNKMSGILNITVQIVGKKILWF
ANNILIFCKDFSYEMKEFLPFLKVSPIESKKIPKNNGSNKPSVHMKFTEMNEKTFVSPLS
NFYFKFENMHKLKYENDCINTNKLWSKCLWKPVFFILPDVNNNSDNNVDVPGTSTHDLVS
TKMNTHVNVNNNNMANNTNDTNYLNHSIIKKKMVPSIIPQSSNEIVIKYNKYHNTYGHIE
YEDQFANTLFVSPNIQIKSEPINITYYMYCKNLQGKKCKLLCMENIKNIRTISIKNYYGF
INLCNQYKHNEKPTSSSMEQKNSNNNVSYSHHNMYQVQQKPYSKIFDTRKNVESENSNNK
ADSILKQHLNRIINKSEDLRINNKGTLDICNKLLLSNECKTNEKKKKTGSNNIGSNTNIH
ELSDNNRGQHTSYYHEQLLSESLSKNVIHSNYINDYFTLNNDNKNNTSSSSNNNNNNKNN
NNNNDNNNDNDNICSNSNNNVHIKYKLNQIPKIRKHIHHNIKYSSIQEINDNSHYSNKNI
IEEKKQKENSNDMHNPKKNEGHYYIADPSNEKEILYDNKNNENGYSNNFLDDNNALHKHV
HNKITLKGSNTYYDMDKIKDKQIEYFSNDSSNYSLYYIGCKEFKLCIDSYDSIFPAKPFI
FNCTVNFKEEENYYHKKNYLTNSVGIIWGIYRWLWKSNGKFICPLRLPLCVSEFPSEKIE
ECEIDVVGYKSNDNLCIEFQPLYQCLLFYKNGTYQFGFKFDTFYNYRNLKNTFLSEHNGD
MNMDRVHQNISKLSYSSSISNANFNDNFFVKRFVHNKYEQVSTEKNDLQKMSKKKDDKIN
NYDDNMMNNYDDGNNNNNNNDSMNNHKDDMNNYNDNINNYVESMNNYDDIMNKGHVVTQN
NLTLNSEHNTKVNISNFFPLSNMSSVSNMYTISNERKSSNKGNGTNNVVKARVERRGKYK
GMNGININNDNDRDEDNNKDKDDGNHDNVNNINSFYNKDRMISYDNLKQEKQNDTVMRIK
NHVNMIKLYNCLLLNDCENVSSILINNPELLTKSNENMSEISFEHYYQMNSDDFPYELIS
SMKNIMHEKYLTPLMLACRIGCEECVQNIIEKGKVNPNKSCHRIEKETPLMVAAQYGHSR
IVCMLICVYGVQVNKKDIKGNTALHKILLNYSNTEGKKNSTIKIVQLLLKLGADLTIKNK
KGISVEDLVQKKLIKNEKIENLLNIWITLIIKNKKKHEGRYIPRNIIPGLLSNCSIVVGF
PKGINGNVPNECGVKINSFVVGGEELVNVRYHKEKPTKHTFDNNYDNNYDNNYDNNYDQD
GGNNIYNNAHSNVYNNGDYKNNLNKDDHPCYINFNYDKLNYNYNKWRVRTKEEEYYSCDN
SSSNSSISKFGNLEKKIIEDHEKYKFSKYGGYPNGLCYKGEKNTHYNKGFEGMNSLEFDA
FSGCKNMYEDTYDKENEEKLLYNNIKDNGLKEIDQEINHSNDNIKAFLKDDDEKDDDEYQ
KPYDKKVINKNKNDNYDKNDNYDKKDNYDTNDKNDKNNCDDNIILSGGKKDKRNKKVMNT
NSSGRRTISKNSPNLSSAKNIKCSKTSTYNSEKYNSNERNSNLENHAIPIDHKDSVDETF
VFIEKQKRNNKINTNDSMTYNPVTHEKENILNYILVHTYIDGKLGIRSASNHDMETEHGM
DNIFETENKKNKALNSNMSNNNNNNNNSNNNNNNNSNNNNNNYNNNYNNNNNNCIYQEFY
MLRKDKKKRKHLILSNLQNNLFNYHDLKYSLIEFINKSGVFSDIIKGHSYLDSKKKIPKF
DELKNSLIEANNELDIIKGFKKFLELFDFLYMDDRLKYFLNIDLRKNLENSRNIVDLGYI
LLKIDSFCCIFNSFKLQWKDNSHEEWKKKLLKGIGILNEFSDIKWITDSYTIFKYEEEIL
ESASFIDKILQNGNYMVFYNNLMNMIHDKNIHLKNGLYDSHIFNDMLKNINIEHFNRDTI
LYDICSKQNILKNYFIQERNKKYAMNNHDSRVINEKYKNYMNEYFVNKKLKGHSNNKDLY
LSMNDSEDELIYSKEKKYKKHQTCDKYIYKSEMKEEMYNKSNELYNNSLNNSNNINNHSE
FYNNGVNRKGDHTYANEKDLSMTSLDCKNHMYGEPQPKDKTYKKGMYDEERKQSMFNTSE
NTEQHDLINKVSGKEEDVRKPKQRNIRSKRLEDIIDKMYEDNDISNRENSKKNIDGLNNI
SGNGRIKFPSYSKNLLRYRNGNFLLNYSNNIFEKGREDESLNSHSPRVTSNLLASYSNER
HGIKLAFMNSGEQGKVMKHTYNDNVSNNVSNNNNIQGEYNHKGDVPHNKFIEKNHYTKNG
TNILSSLNKHNHLNTQEENNSLENNYSCETFCDEYDSEESEFELICEVHFTSKPNEEIMT
REQFNKMWPQTLDMYILHIYDLISSYMDSPEKISLFIYHAFDMEKIKKKLPSKSSQLWKR
INMSLDDFIEEIKNVHNYTMRIIYQSNYKRYGMLPPNFKKYFTLSEECLKNIAKNKIIMN
MDYYKNYIYEENKKMFLKIIQDRIYLLNKFNIYFENCLPITSILFNKPVINLEEQGLRTL
ECPLCFFMSNDSYFPWTYKKRNTHLFQYNNNNNLCLVQKMRSELYDNNNLMSKNVSMLSL
YNNTNYSNNDNNSIVGQSNYPIKVEGNHINENYKNCAEHNHYDYSLNKNYSNEKSIYVKN
SKQIDDIKKIKSGNEYIIMDSIQSLDKNSTIVKKGSFFLNNGKGSYNSYTEIEDKDWLLG
NVENLNNHNIYPDNEINYKNNNHEDNNYNCYQNHLCGNESEEENEIFDCEKYCKNMYTSN
KMVLAMGSSDLPIQLSSYLFIKKLLKHDTCLKLWKECLKYITSSSSEKSNLTLRIDRGMA
ATAKHIAHTMWYQSTYSLLNIDTDKLRGKPRDRPFMVVFVGEGATDFGGPFHEYLSSISR
EVMGKLSDSPDKSLPVFPLCIPCPNYTQAIGARQDTVIINPQSTPYVVKEWDYIGEVDVI
DNLESFRWQILNIYNSIKDIKKKLQKTAKDSYEDYKQKMEENGSDDGLENIMPVKGKSKT
KGKYKKKNKSNKMNMGSDNILKDGVHKDNNNQKGHKYDEKNICNDKNIQEMTSKEKMYFY
TSKKSVTFEKLEENEKMDYQIENKYDYPFVCDACEYDSDIYEIINNASLKSRKLFMNKIW
KKKKCLDDEGDKNVLLRDPHENENMRDDIRNNMNNNNNNNNNNNNNNNNNNNNNNNNNNN
NNNNNNNNNLNSIGGSKNTMTDGKKKNKFIIDYDEKTIKAMELAMYESLGRVMGMCVCIA
SALNICFNPIIWKKICGVPLELQDLADYDFVAVEMLKTLKMLNSEKSNEWNMELKQSLGD
MTFITEDSGGNSIELIKNGMNIPINFDNLGLFIRLMTKCKMNESSKGIRHLLKGFSSVIP
LGRLRLLYDFKDVEHMVCGEREINIEVLKAHTWSNDLNIKDKLFTVLEEFTNEQLQSFLR
FVSGRSRLPTTKNDWYMIIDVENPNKNISQIDQRLPTAVTCGFRLLLPQYSSLDILKERL
LYAIKNCTAIDLDAYVVHDQMQLMYGE
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Apical membrane antigen 1
MRKLYCVLLLSAFEFTYMINFGRGQNYWEHPYQNSNVYHPINEHREHPKEYQYPLHQEHT
YQQEDSGEDENTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIE
EVHGSGIRVDLGEDAEVAGTQYRLPSGKCPVFGKGIIIENSNTTFLKPVATGNQDLKDGG
FAFPPTEPLISPMTLNGMRDFYKNNEYVKNLDELTLCSRHAGNMNPDKDENSNYKYPAVY
DDKDKKCHILYIAAQENNGPRYCNKDESKRNSMFCFRPAKDKSFQNYTYLSKNVVDNWEK
VCPRKNLENAKFGLWVDGNCEDIPHVNEFSANDLFECNKLVFELSASDQPKQYEQHLTDY
EKIKEGFKNKNASMIKSAFLPTGAFKADRYKSHGKGYNWGNYNRKTHKCEIFNVKPTCLI
NNSSYIATTALSHPIEVENNFPCSLYKNEIMKEIERESKRIKLNDNDDEGNKKIIAPRIF
ISDDKDSLKCPCDPEMVSNSTCRFFVCKCVERRAEVTSNNEVVVKEEYKDEYADIPEHKP
TYDNMKIIIASSAAVAVLATILMVYLYKRKGNAEKYDKMDQPQDYGKSTSRNDEMLDPEA
SFWGEEKRASHTTPVLMEKPYY
ENDING
Apical membrane antigen 1
MRKLYCVLLLSAFEFTYMINFGRGQNYWEHPYQKSGVYHPINEHREHPKEYEYPLHQEHT
YQQEDSGEDENTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIE
EVHGSGIRVDLGEDAEVAGTQYRLPSGKCPVFGKGIIIENSNTTFLKPVATGNQDLKDGG
FAFPPTNPLISPMTLNGMRDFYKNNEYVKNLDELTLCSRHAGNMNPDNDKNSNYKYPAVY
DYNDKKCHILYIAAQENNGPRYCNKDQSKRNSMFCFRPAKDKLFENYTYLSKNVVDNWEE
VCPRKNLENAKFGLWVDGNCEDIPHVNEFSANDLFECNKLVFELSASDQPKQYEQHLTDY
EKIKEGFKNKNASMIKSAFLPTGAFKADRYKSHGKGYNWGNYNRETQKCEIFNVKPTCLI
NNSSYIATTALSHPIEVEHNFPCSLYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIF
ISDDKDSLKCPCDPEMVSNSTCRFFVCKCVERRAEVTSNNEVVVKEEYKDEYADIPEHKP
TYDNMKIIIASSAAVAVLATILMVYLYKRKGNAEKYDKMDQPQHYGKSTSRNDEMLDPEA
SFWGEEKRASHTTPVLMEKPYY
ENDING
ENDING
ENDING
ENDING
ENDING
Merozoite surface protein 1
MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYGLFHKEKMILNEEEITT
KGASAQSGTSGTSGTSGTSGTSGTSGTSAQSGTSGTSAQSGTSGTSAQSGTSGTSGTSGT
SPSSRSNTLPRSNTSSGASPPADASDSDAKSYADLKHRVRNYLFTIKELKYPELFDLTNH
MLTLCDNIHGFKYLIDGYEEINELLYKLNFYFDLLRAKLNDVCANDYCQIPFNLKIRANE
LDVLKKLVFGYRKPLDNIKDNVGKMEDYIKKNKTTIANINELIEGSKKTIDQNKNADNEE
GKKKLYQAQYDLSIYNKQLEEAHNLISVLEKRIDTLKKNENIKELLDKINEIKNPPPANS
GNTPNTLLDKNKKIEEHEEKIKEIAKTIKFNIDSLFTDPLELEYYLREKNKKVDVTPKSQ
DPTKSVQIPKVPYPNGIVYPLPLTDIHNSLAADNDKNSYGDLMNPDTKEKINEKIITDNK
ERKIFINNIKKQIDLEEKKINHTKEQNKKLLEDYEKSKKDYEELLEKFYEMKFNNNFDKD
VVDKIFSARYTYNVEKQRYNNKFSSSNNSVYNVQKLKKALSYLEDYSLRKGISEKDFNHY
YTLKTGLEADIKKLTEEIKSSENKILEKNFKGLTHSANASLEVYDIVKLQVQKVLLIKKI
EDLRKIELFLKNAQLKDSIHVPNIYKPQNKPEPYYLIVLKKEVDKLKEFIPKVKDMLKKE
QAVLSSITQPLVAASETTEDGGHSTHTLSQSGETEVTEETEETEETVGHTTTVTITLPPK
EVKVVENSIEHKSNDNSQALTKTVYLKKLDEFLTKSYICHKYILVSNSSMDQKLLEVYNL
TPEEENELKSCDPLDLLFNIQNNIPAMYSLYDSMNNDLQHLFFELYQKEMIYYLHKLKEE
NHIKKLLEEQKQITGTSSTSSPGNTTVNTAQSATHSNSQNQQSNASSTNTQNGVAVSSGP
AVVEESHDPLTVLSISNDLKGIVSLLNLGNKTKVPNPLTISTTEMEKFYENILKNNDTYF
NDDIKQFVKSNSKVITGLTETQKNALNDEIKKLKDTLQLSFDLYNKYKLKLDRLFNKKKE
LGQDKMQIKKLTLLKEQLESKLNSLNNPHNVLQNFSVFFNKKKEAEIAETENTLENTKIL
LKHYKGLVKYYNGESSPLKTLSEVSIQTEDNYANLEKFRVLSKIDGKLNDNLHLGKKKLS
FLSSGLHHLITELKEVIKNKNYTGNSPSENNKKVNEALKSYENFLPEAKVTTVVTPPQPD
VTPSPLSVRVSGSSGSTKEETQIPTSGSLLTELQQVVQLQNYDEEDDSLVVLPIFGESED
NDEYLDQVVTGEAISVTMDNILSGFENEYDVIYLKPLAGVYRSLKKQIEKNIFTFNLNLN
DILNSRLKKRKYFLDVLESDLMQFKHISSNEYIIEDSFKLLNSEQKNTLLKSYKYIKESV
ENDIKFAQEGISYYEKVLAKYKDDLESIKKVIKEEKEKFPSSPPTTPPSPAKTDEQKKES
KFLPFLTNIETLYNNLVNKIDDYLINLKAKINDCNVEKDEAHVKITKLSDLKAIDDKIDL
FKNHNDFEAIKKLINDDTKKDMLGKLLSTGLVQNFPNTIISKLIEGKFQDMLNISQHQCV
KKQCPENSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTCNENNGGCDADAKCTEEDSG
SNGKKITCECTKPDSYPLFDGIFCSSSNFLGISFLLILMLILYSFI
ENDING
ENDING
Merozoite surface protein 1
MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYSLFQKEKMVLKDGANTQ
VVAKPADAVSTQSAKNPPGATVPSGTASTKGAIRSPGAANPSDDSSDSDAKSYADLKHRV
QNYLFTIKELKYPELFDLTNHMLTLCDNIHGFKYLIDGYEEINELLYKLNFYFDLLRAKL
NDVCANDYCQIPFNLKIRANELDVLKKLVFGYRKPLDFIKDNVGKMEDYIKKNKTTIANI
NELIEGSKKTIDQNKNADNEEGKKKLYQAQYDLFIYNKQLQEAHNLISVLEKRIDTLKKN
ENIKKLLEDIDKIKIDAEKPTTGVNQILSLRLEKESRHEEKIKEIAKTIKFNIDRLFTDP
LELEYYLREKNKKVDVTPKSQDPTKSVQIPKVPYPNGIVYPLPLTDIHNSLAADNDKNSY
GDLMNPHTKEKINEKIITDNKERKIFINNIKKQIDLEEKNINHTKEQNKKLLEDYEKSKK
DYEELLEKFYEMKFNNNFNKDVVDKIFSARYTYNVEKQRYNNKFSSSNNSVYNVQKLKKA
LSYLEDYSLRKGISEKDFNHYYTLKTGLEADIKKLTEEIKSSENKILEKNFKGLTHSANA
SLEVSDIVKLQVQKVLLIKKIEDLRKIELFLKNAQLKDSIHVPNIYKPQNKPEPYYLIVL
KKEVDKLKEFIPKVKDMLKKEQAVLSSITQPLVAASETTEDGGHSTHTLSQSGETEVTEE
TEETVGHTTTVTITLPPKEVKVVENSIEHKSNDNSQALTKTVYLKKLDEFLTKSYICHKY
ILVSNSSMDQKLLEVYNLTPEENELKSCDRLDLLFNIQNNIPAMYSLYDSMNNDLQHLFF
ELYQKEMIYYLHKLKEENHIKKLLEEPKQITGTSSTSSPGNTTVNTAQSATHSNSQNQQS
NASSTNTQNGVAVSSGPAVVEESHDPLTVLSISNDLKGIVSLLNLGNKTKVPNPLTISTT
EMEKFYENILKIMIPIFNDDIKQFVKSNSKVITGLTETQKNALNDEIKKLKDTLQLSFDL
YNKYKLKLDRLFNKKKELGQDKMQIKKLTLLKEQLESKLNSLNNPHNVLQNFSVFFNKKK
EAEIAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEVSIQTEDNYANLEKFRVLSK
IDGKLNDNLHLGKKKLSFLSSGLHHLITELKEVIKNKNYTGNSPSENNKKVNEALKSYEN
FLPEAKVTTVVTPPQPDVTPSPLSVRVSGSSGSTKEETQIPTSGSLLTELQQVVQLQNYD
EEDDSLVVLPIFGESEDNDEYLDQVVTGEAISVTMDNILSGFENEYDVIYLKPLAGVYRS
LKKQIEKNIFTFNLNLNDILNSRLKKRKYFLDVLESDLMQFKHISSNEYIIEDSFKLLNS
EQKNTLLKSYKYIKESVENDIKFAQEGISYYEKVLAKYKDDLESIKKVIKEEKEFPSSPP
TTPPSPAKTDEQKKESKFLPFLTNIETLYNNLVNKIDDYLINLKAKINDCNVEKDEAHVK
ITKLSDLKAIDDKIDLFKNPYDFEAIKKLINDDTKKDMLGKLLSTGLVQNFPNTIISKLI
EGKFQDMLNISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTCNEN
NGGCDADAKCTEEDSGSNGKKITCECTKPDSYPLFDGIFCSSSNFLGISFLLILMLILYS
FI
ENDING
Merozoite surface protein 1
MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYSLFQKEKMVLNEGTSGT
AVTTSTPGSSGSVTSGGSVASVASVASGGSGGSVASGGSGNSRRTNPSDNSSDSNTKTYA
DLKHRVQNYLFTIKELKYPELFDLTNHMLTLSKNVDGFKYLIDGYEEINELLYKLNFYYD
LLRAKLNDACANSYCQIPFNLKIRANELDVLKKIVFGYRKPLDNIKDNVGKMEDYIKKNK
TTIANINELIEGSKKTIDQNKNADNEEGKKKLYQAQYNLFIYNKQLQEAHNLISVLEKRI
DTLKKNENIKKLLEDIDKIKTDAENPTTGSKPNPLPENKKKEVEGHEEKIKEIAKTIKFN
IDSLFTDPLELEYYLREKNKKVDVTPKSQDPTKSVQIPKVPYPNGIVYPLPLTDIHNSLA
ADNDKNSYGDLMNPDTKEKINEKIITDNKERKIFINNIKKQIDLEEKNINHTKEQNKKLL
EDYEKSKKDYEELLEKFYEMKFNNNFDKDVVDKIFSARYTYNVEKQRYNNKFSSSNNSVY
NVQKLKKALSYLEDYSLRKGISEKDFNHYYTLKTGLEADIKKLTEEIKSSENKILEKNFK
GLTHSANASLEVSDIVKLQVQKVLLIKKIEDLRKIELFLKNAQLKDSIHVPNIYKPQNKP
EPYYLIVLKKEVDKLKEFIPKVKDMLKKEQAVLSSITQPLVAASETTEDGGHSTHTLSQS
GETEVTEETEVTEETVGHTTTVTITLPPKEESAPKEVKVVENSIEHKSNDNSQALTKTVY
LKKLDEFLTKSYICHKYILVSNSSMDQKLLEVYNLTPEEENELKSCDPLDLLFNIQNNIP
AMYSLYDSMNNDLQHLFFELYQKEMIYYLHKLKEENHIKKLLEEQKQITGTSSTSSPGNT
TVNTAQSATHSNSQNQQSNASSTNTQNGVAVSSGPAVVEESHDPLTVLSISNDLKGIVSL
LNLGNKTKVPNPLTISTTEMEKFYENILKNNDTYFNDDIKQFVKSNSKVITGLTETQKNA
LNDEIKKLKDTLQLSFDLYNKYKLKLDRLFNKKKELGQDKMQIKKLTLLKEQLESKLNSL
NNPHNVLQNFSVFFNKKKEAEIAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEVS
IQTEDNYANLEKFRALSKIDGKLNDNLHLGKKKLSFLSSGLHHLITELKEVIKNKNYTGN
SPSENNKKVNEALKSYENFLPEAKVTTVVTPPQPDVTPSPLSVRVSGSSGSTKEETQIPT
SGSLLTELQQVVQLQNYDEEDDSLVVLPIFGESEDNDEYLDQVVTGEAISVTMDNILSGF
ENEYDVIYLKPLAGVYRSLKKQIEKNIITFNLNLNDILNSRLKKRKYFLDVLESDLMQFK
HISSNEYIIEDSFKLLNSEQKNTLLKSYKYIKESVENDIKFAQEGISYYEKVLAKYKDDL
ESIKKVIKEEKEKFPSSPPTTPPSPAKTDEQKKESKFLPFLTNIETLYNNLVNKIDDYLI
NLKAKINDCNVEKDEAHVKITKLSDLKAIDDKIDLFKNTNDFEAIKKLINDDTKKDMLGK
LLSTGLVQNFPNTIISKLIEGKFQDMLNISQHQCVKKQCPENSGCFRHLDEREECKCLLN
YKQEGDKCVENPNPTCNENNGGCDADATCTEEDSGSSRKKITCECTKPDSYPLFDGIFCS
SSNFLGISFLLILMLILYSFI
ENDING
ENDING
ENDING
ENDING
Apical membrane antigen 1
MRKLYCVLLLSAFEFTYMINFGRGQNYWEHPYQKSDVYHPINEHREHSKEYEYPLHQEHT
YQQEDSGEDENTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIK
EVHGSGIRVDLGEDAEVAGTQYRLPSGKCPVFGKGIIIENSNTTFLKPVATGNQDLKDGG
FAFPPTNPLISPMTLDHMRDFYKNNEYVKNLDELTLCSRHAGNMNPDNDKNSNYKYPAVY
DYNDKKCHILYIAAQENNGPRYCNKDESKRNSMFCFRPAKDKSFQNYTYLSKNVVDNWEK
VCPRKNLENAKFGLWVDGNCEDIPHVNEFSANDLFECNKLVFELSASDQPKQYEQHLTDY
EKIKEGFKNKNASMIKSAFLPTGAFKADRYKSRGKGYNWGNYNRKTQKCEIFNVKPTCLI
NNSSYIATTALSHPNEVEHNFPCSLYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIF
ISDDIDSLKCPCDPEIVSNSTCNFFVCKCVEKRAEVTSNNEVVVKEEYKDEYADIPEHKP
TYDKMKIIIASSAAVAVLATILMVYLYKRKGNAEKYDKMDEPQDYGKSNSRNDEMLDPEA
SFWGEEKRASHTTPVLMEKPYY
ENDING
Apical membrane antigen 1
MRKLYCVLLLSAFEFTYMINFGRGQNYWEHPYQNSDVYRPINEHREHPKEYEYPLLQEHT
YQQEDSGEDENTLQHAYPIDHEGAEPAPQEQNLFSSIEIVERSNYMGNPWTEYMAKYDIE
KVHGSGIRVDLGEDAEVAGTQYRLPSGKCPVFGKGIIIENSKTTFLTPVATENQDLKDGG
FAFPPTEPLISPMTLDQMRHLYKDNEYVKNLDELTLCSRHAGNMNPDNDKNSNYKYPAVY
DYEDKKCHILYIAAQENNGPRYCNKDESKRNSMFCFRPAKDKLFENYTYLSKNVVDNWEE
VCPRKNLENAKFGLWVDGNCEDIPHVNEFSANDLFECNKLVFELSASDQPKQYEQHLTDY
EKIKEGFKNKNASMIKSAFLPTGAFKADRYKSRGKGYNWGNYNTETQKCEIFNVKPTCLI
NNSSYIATTALSHPNEVENNFPCSLYKDEIKKEIERESKRIKLNDNDDEGNKKIIAPRIF
ISDDKDSLKCPCDPEIVSNSTCNFFVCKCVEKRAEVTSNNEVVVKEEYKDEYADIPEHKP
TYDNMKIIIASSAAVAVLATILMVYLYKRKGNAEKYDKMDEPQDYGKSTSRNDEMLDPEA
SFWGEEKRASHTTPVLMEKPYY
ENDING
ENDING
101 kDa malaria antigen
MMNMKIVLFSLLLFVIRWNIISCNKNDKNQGVDMNVLNNYENLFKFVKCEYCNEHTYVKG
KKAPSDPQCADIKEECKELLKEKQYTDSVTYLMDGFKSANNSANNGKKNNAEEMKNLVNF
LQSHKKLIKALKKNIESIQNKKHLIYKNKSYNPLLLSCVKKMNMLKENVDYIQKNQNLFK
ELMNQKATYSFVNTKKKIISLKSQGHKKETSQNQNENNDNQKYQEVNDEDDVNDEEDTND
DEDTNDEEDTNDDEDTNDDEDTNDEEDTNDEEDHENNNATAYELGIVPVNDVLNVNMKNM
ITGNNFMDVVKNTLAQSGGLGSNDLINFLNQGKEIGENLLNITKMNLGDKNNLESFPLDE
LNMLKDNLINYEFILDNLKTSVLNKLKDLLLRLLYKAYVSYKKRKAQEKGLPEPTVTNEE
YVEELKKGILDMGIKLLFSKVKSLLKKLKNKIFPKKKEDNQAVDTKSMEEPKVKAQPALR
GVEPTEDSNIMNSINNVMDEIDFFEKELIENNNTPNVVPPTQSKKKNKNETVSGMDENFD
NHPENYFKEEYYYDENDDMEVKVKKIGVTLKKFEPLKNGNVSETIKLIHLGNKDKKHIEA
INNDIQIIKQELQAIYNELMNYTNGNKNIQQIFQQNILENDVLNQETEEEMEKQVEAITK
QIEAEVDALAPKNKEEEEKEKEKEEKEKEEKEKEKEEKEKEEKEKEEKEKEEKEEEKKEK
EEEQEEEEEEEIVPENLTTEESK
ENDING
ENDING
ENDING
Merozoite surface protein 1
MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYGLFHKEKMILNEEEITT
KGASAQSGTSGTSGTSGTSGTSGTSGTSAQSGTSGTSAQSGTSGTSAQSGTSGTSGTSGT
SPSSRSNTLPRSNTSSGASPPADASDSDAKSYADLKHRVRNYLFTIKELKYPELFDLTNH
MLTLCDNIHGFKYLIDGYEEINELLYKLNFYFDLLRAKLNDVCANDYCQIPFNLKIRANE
LDVLKKLVFGYRKPLDNIKDNVGKMEDYIKKNKTTIANINELIEGSKKTIDQNKNADNEE
GKKKLYQAQYDLSIYNKQLEEAHNLISVLEKRIDTLKKNENIKELLDKINEIKNPPPANS
GNTPNTLLDKNKKIEEHEEKIKEIAKTIKFNIDSLFTDPLELEYYLREKNKKVDVTPKSQ
DPTKSVQIPKVPYPNGIVYPLPLTDIHNSLAADNDKNSYGDLMNPDTKEKINEKIITDNK
ERKIFINNIKKQIDLEEKKINHTKEQNKKLLEDYEKSKKDYEELLEKFYEMKFNNNFDKD
VVDKIFSARYTYNVEKQRYNNKFSSSNNSVYNVQKLKKALSYLEDYSLRKGISEKDFNHY
YTLKTGLEADIKKLTEEIKSSENKILEKNFKGLTHSANASLEVYDIVKLQVQKVLLIKKI
EDLRKIELFLKNAQLKDSIHVPNIYKPQNKPEPYYLIVLKKEVDKLKEFIPKVKDMLKKE
QAVLSSITQPLVAASETTEDGGHSTHTLSQSGETEVTEETEETEETVGHTTTVTITLPPK
EVKVVENSIEHKSNDNSQALTKTVYLKKLDEFLTKSYICHKYILVSNSSMDQKLLEVYNL
TPEEENELKSCDPLDLLFNIQNNIPAMYSLYDSMNNDLQHLFFELYQKEMIYYLHKLKEE
NHIKKLLEEQKQITGTSSTSSPGNTTVNTAQSATHSNSQNQQSNASSTNTQNGVAVSSGP
AVVEESHDPLTVLSISNDLKGIVSLLNLGNKTKVPNPLTISTTEMEKFYENILKNNDTYF
NDDIKQFVKSNSKVITGLTETQKNALNDEIKKLKDTLQLSFDLYNKYKLKLDRLFNKKKE
LGQDKMQIKKLTLLKEQLESKLNSLNNPHNVLQNFSVFFNKKKEAEIAETENTLENTKIL
LKHYKGLVKYYNGESSPLKTLSEVSIQTEDNYANLEKFRVLSKIDGKLNDNLHLGKKKLS
FLSSGLHQLITELKEVIKNKNYTGNSPSENNKKVNEALKSYENFLPEAKVTTVVTPPQPD
VTPSPLSVRVSGSSGSTKEETQIPTSGSLLTELQQVVQLQNYDEEDDSLVVLPIFGESED
NDEYLDQVVTGEAISVTMDNILSGFENEYDVIYLKPLAGVYRSLKKQIEKNIFTFNLNLN
DILNSRLKKRKYFLDVLESDLMQFKHISSNEYIIEDSFKLLNSEQKNTLLKSYKYIKESV
ENDIKFAQEGISYYEKVLAKYKDDLESIKKVIKEEKEKFPSSPPTTPPSPAKTDEQKKES
KFLPFLTNIETLYNNLVNKIDDYLINLKAKINDCNVEKDEAHVKITKLSDLKAIDDKIDL
FKNHNDFDAIKKLINDDTKKDMLGKLLSTGLVQNFPNTIISKLIEGKFQDMLNISQHQCV
KKQCPENSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTCNENNGGCDADAKCTEEDSG
SNGKKITCECTKPDSYPLFDGIFCSSSNFLGISFLLILMLILYSFI
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
S-antigen protein
MNRILSVTFYLFFIYLYIYETYGKVKNTDKELSDIYGTKYYLRSGFFNSKKCKGHKYEDL
QAEGEGENDKEEDSNNEEMNIDEENGLIEGQGESEDPAKASQGGLEDPAKASQGGLEDPA
KASQGGLEDPAKASQGGLEDPAKASQGGLEDPAKASQGGLEDPAKASQGGLEDPAKASQG
GLEDPAKASQGGLEDPAKASQGGLEDPAKASQGGLEDPAKASQGGLEDPAKASQGGAEGH
GKHAPNKENKNKNKESIKNIMNMFI
ENDING
ENDING
S-antigen protein
MNRILSVSFYLFFLYLYIYKTYGKVKNTDQEISNIYGTNYYLRNGFLNGKNGKGNKYEDL
QEEGEGENDDEEHSNSEESDNDEENEIIVGQDGSDQEVKVQKEQGGPGSEGPKGTGGPGS
EGPKGTGGPGSEGPKGTGGPGSEGPKGTGGPGSEGPKGTGGPGSEGPKGTGGPGSEGPKG
TGGPGSEGPKGTGGPGSEGPKGTGGPGSEGPKGTGGPGSEGPKGTGGPGSEGPKGTGGPG
SEGPKGTGGPGSEGPKGTGGPGSEGPKGTGGPGSEGPKGTGGPGSESPKGTGGPGSEGPK
GTGGPGSEGPKGTGPKGTGGPGSEAGTEGPKGTGGPGSEAGTEGPKGTGGPGSGGEHSHN
KKKSKKSIMNMLIGV
ENDING
S-antigen protein
MNRILSVSFYLFFLYLYIYKTYGKVKNTDQEISNIYGTNYYLRNGFLNGKNGKGNKYEDL
QEEGEGENDDEEHSNSEESDNDEENEIIVGQDEAPKSDEAEALKSDEAEALKSDEAEARK
SDEAEALKSDEAEARKSDEAEALKSDEAEALKSDEAEARKSDEAEALKSDEAEALKSDEA
EARKSDEAEARKSDEAEARKSDEAEARKSDEAEALKSDEAEARKSDEAEARKSDEAEALK
SDEAEARKSDEAEARKSEAGTEGPKGTGGPGSEAGTEGPKGTGGPGSGGEHSHNKKKSKK
SIMNMLILM
ENDING
S-antigen protein
MNRILSVSFYLFFLYLYIYKTYGKVKNTDHELSNIYGIKYYLRNGLSDKKNGKGQKYQDL
EEDENDDEEDSNSEESNNDEENKLIEGQEGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGD
KGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPN
SDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGD
KGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPN
SDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGD
KGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPN
SDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGD
KGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPN
SDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGDKGPNSDGD
KGPNSDGDKGPNSDGEHSRSKNDNKKKKSKKNIINMFIGM
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Merozoite surface protein 1
MKIIFFLCSFLFFIINTQCVTHESYQELVKKLEALEDAVLTGYSLFQKEKMVLNEGTSGT
AVTTSTPGSSGSVTSGGSVASVASVASGGSGGSVASGGSGNSRRTNPSDNSSDSNTKTYA
DLKHRVQNYLFTIKELKYPELFDLTNHMLTLSKNVDGFKYLIDGYEEINELLYKLNFYYD
LLRAKLNDACANSYCQIPFNLKIRANELDVLKKIVFGYRKPLDNIKDNVGKMEDYIKKNK
TTIANINELIEGSKKTIDQNKNADNEEGKKKLYQAQYNLFIYNKQLQEAHNLISVLEKRI
DTLKKNENIKKLLEDIDKIKTDAENPTTGSKPNPLPENKKKEVEGHEEKIKEIAKTIKFN
IDSLFTDPLELEYYLREKNKKVDVTPKSQDPTKSVQIPKVPYPNGIVYPLPLTDIHNSLA
ADNDKNSYGDLMNPDTKEKINEKIITDNKERKIFINNIKKQIDLEEKNINHTKEQNKKLL
EDYEKSKKDYEELLEKFYEMKFNNNFDKDVVDKIFSARYTYNVEKQRYNNKFSSSNNSVY
NVQKLKKALSYLEDYSLRKGISEKDFNHYYTLKTGLEADIKKLTEEIKSSENKILEKNFK
GLTHSANASLEVSDIVKLQVQKVLLIKKIEDLRKIELFLKNAQLKDSIHVPNIYKPQNKP
EPYYLIVLKKEVDKLKEFIPKVKDMLKKEQAVLSSITQPLVAASETTEDGGHSTHTLSQS
GETEVTEETEVTEETVGHTTTVTITLPPKEESAPKEVKVVENSIEHKSNDNSQALTKTVY
LKKLDEFLTKSYICHKYILVSNSSMDQKLLEVYNLTPEEENELKSCDPLDLLFNIQNNIP
AMYSLYDSMNIDLQHLFFELYQKEMIYYLHKLKEENHIKKLLEEQKQITGTSSTSSPGNT
TVNTAQSATHSNSQNQQSNASSTNTQNGVAVSSGPAVVEESHDPLTVLSISNDLKGIVSL
LNLGNKTKVPNPLTISTTEMEKFYENILKNNDTYFNDDIKQFVKSNSKVITGLTETQKNA
LNDEIKKLKDTLQLSFDLYNKYKLKLDRLFNKKKELGQDKMQIKKLTLLKEQLESKLNSL
NNPHNVLQNFSVFFNKKKEAEIAETENTLENTKILLKHYKGLVKYYNGESSPLKTLSEVS
IQTEDNYANLEKFRALSKIDGKLNDNLHLGKKKLSFLSSGLHHLITELKEVIKNKNYTGN
SPSENNKKVNEALKSYENFLPEAKVTTVVTPPQPDVTPSPLSVRVSGSSGSTKEETQIPT
SGSLLTELQQVVQLQNYDEEDDSLVVLPIFGESEDNDEYLDQVVTGEAISVTMDNILSGF
ENEYDVIYLKPLAGVYRSLKKQIEKNIITFNLNLNDILNSRLKKRKYFLDVLESDLMQFK
HISSNEYIIEDSFKLLNSEQKNTLLKSYKYIKESVENDIKFAQEGISYYEKVLAKYKDDL
ESIKKVIKEEKEKFPSSPPTTPPSPAKTDEQKKESKFLPFLTNIETLYNNLVNKIDDYLI
NLKAKINDCNVEKDEAHVKITKLSDLKAIDDKIDLFKNTNDFEAIKKLINDDTKKDMLGK
LLSTGLVQNFPNTIISKLIEGKFQDMLNISQHQCVKKQCPENSGCFRHLDEREECKCLLN
YKQEGDKCVENPNPTCNENNGGCDADATCTEEDSGSSRKKITCECTKPDSYPLFDGIFCS
SSNFLGISFLLILMLILYSFI
ENDING
ENDING
ENDING
Knob-associated histidine-rich protein
MKSFKNKNTLRRKKAFPVFTKILLVSFLVWVLKCSNNCNNGNGSGDSFDFRNKRTLAQKQ
HEHHHHHHHQHQHQHQAPHQAHHHHHHGEVNHQAPQVHQQVHGQDQAHHHHHHHHHQLQP
QQLQGTVANPPSNEPVVKTQVFREARPGGGFKAYEEKYESKHYKLKENVVDGKKDCDEKY
EAANYAFSEECPYTVNDYSQENGPNIFALRKRFPLGMNDEDEEGKEALAIKDKLPGGLDE
YQNQLYGICNETCTTCGPAAIDYVPADAPNGYAYGGSAHDGSHGNLRGHGNKGSEGYGYE
APYNPGFNGAPGSNGMQNYVPPHGAGYSAPYGVPHGAAHGSRYSSFSSVNKYGKHGDEKH
HSSKKHEGNDGEGEKKKKSKKHKDHDGEKKKSKKHKDNEDAESVKSKKHKSHDCEKKKSK
KHKDNEDAESVKSKKSVKEKGEKHNGKKPCSKKTNEENKNKEKTNNLKSDGSKAHEKKEN
ETKNTAGENKKVDSTSADNKSTNAATPGAKDKTQGGKTDKTGASTNAATNKGQCAAEGAT
KGATKEASTSKEATKEASTSKGATKEASTTEGATKGASTTAGSTTGATTGANAVQSKDGT
ADKNAANNGEQVMSRGQAQLQEAGKKKKKRGCCG
ENDING
ENDING
ENDING
ENDING
ENDING
Protein dopey homolog PFC0245c
MIKKSEESKRLLRKKLNNDITNILLLFEKVQEWADLSNILQKLYLTIEKYELFVNVSSKF
LLFRRLSQCLNPLLPSGVHSKALIIYSSIFKKVEMDFFINNIHILCSGIFEFMLHCTINL
KTIYFKNIKSILRLKENVYIFAYALLLSLFNVVDSDNNILLYIYSINNYIGENIFFNNIW
LLLLRHPEIRTNILNFLEASFSPQIYLLSKERIKMLLPYKDHLVLSSIIYCLNDKNILNQ
RITLSLLINNFPLSHVPNKKNKKKIIDKSKSNDYHMDKPPYSPFNASTSSVILNNSNMDS
MNDNRINENNINNNDNKRHNIQINNDYLFGDMMNKQNDTTIMQSNKMLNRHNIIGEQHLD
DDLLSSIHDDNSEKKNNNNFMLLNENNKISTSKEHLDNMHNRGIKSHEDIMGSNQNKMNL
SNDEKDHWGGNLNSKVGNYDDKNICGKKHLGLKSEYGQVSYDESLERRLNNNNNNNNNNN
NNNNNNGDNLKYQGSVDYDEHDISMSTENDKYGKMGNENMNDVFISKGKMMRKGYEDDGH
HHININDDDNLNYDDNEDDEYGNYHNNNYNDRNYFNEYDEDDQYENNNNNNHSNNNNMLH
LGSVDRNRRKQLKKKINNIGQTNNYDDDEEEEDEEEEDNNNNTSYNNNNNNSSSSSSIFF
SDTSKKLIARNVIFLLKKSDIGLNRRIFKYLYLYESNDEKNFKDKEINFENYKIYCETII
DILENKSDDNYNSIAEVIYILFKNKDYININRYIMEQVFLYLLNFCYKNREDTSIKSFLK
NMLNLNLISYENILNIFLYTFYYLRRNDDLFVHYTNIYIKKYINLLNIMTFFVEFIKHMN
KYLYIQFLFHFNLATLKLMNFLNLKIINIIKKYSHVKDLNEKYFIDSNDVVSGRHSTLYY
FYFFVTHYNNYYLNKCLSIIVKDILPQNPSNRKMGNYQSHYYANNKHMLYMNTHEIHSAR
MEEYSNKIQKVGFKNEIVDRKNKYDNNEYSESEIKMRAVDNSMNYIKRKVKKKNMESKDS
SNSMSNMEINTNSTMANRLNHMQHIQHDGISSMEHMNNKINDNNNNNNVNYFFDGNNSNN
NNNNNILENNNKLYFDKGYNGNYSKIENDQSFHNILMKYKFKLKQNLIDAIIKNHELYFF
TNNCEYIIFLFYNYHLLIEKEKLNKSCFYFLKNILNNCTCENKNKFYFWCFLFLHIIRIN
FNKSLLKNYKIKEAGDDTDDDDDDDDDDDDEEEDDDDEDDDDEDDEEEDDEEDLGVDGLK
NMSSKKGKKKKKKSVHKNKLMNKKYGRGGSSKYYYYLTSDKEIMLHGGMMGGVNYSDMEH
DEDNLDVDDEDEQMFSYNKNKIRNKHFGELNKMKYMNEDITNNNNNINNNSNNNNNNKNN
INNNNNNNNNNNNNNNNLNNLNNFNNNVSINNGNNKYRNYFRSTEEELLFNKRFVEFLLP
YSNNIAKYIFQYIKILKKNKKFIKLFFDINYLYFFCDNMFCLKILKKSLKCKDNHELTIN
VKVILEYIINSKTNEYHIIHSNFYNLTHDVFKLYNRRNNLINYYLIKYIMRNKENLSYIF
DNIIISMFDLITEIENLYEKIEMMKKDLSYSMMNNNDHVYDPNGMIEAADQRKSHYVSLK
DNMNNMNNMNNVNNMNNVNNMNNVNNVNNVNNVNYHNNTINNNNNNNNFSNHTSYVNEKT
QENNYHNLMNTYEKYLKKLKCKFDYISYFFLNMENFMLWLYKHKISKKIYHSRNKMTLTN
YEKNMAIIICYICTEGNINSFFFRNYLDVFFILFLKIIYLNENISELNNSANNIIQKEKN
NLKHNSLLEFKRDTLSMLNNIFNINHNKKFEYMKILNLYYRQIIHHLLFLYYYFTVKKYY
VLQLQLVHFIRYILPLYEKNIDKKFLTNESTEKDKVFKRMKYNNYEEFISASKYHFEIIN
RNNYNMKNDVFIFSILRKSMTIIFNLNEQVLYKEVLKTIIDLIENIIDEKEVKNYYLTVF
FLDLLYIIKMEDQKKKKNIFFIMKFCQFLIEIFKLIYRDEMKNELKCDKKFQDDNITIDI
IENALSNNKMSTASFCTIFSIKTDDKFVNVQHKNISNLFSVIFNLYAFLKKKIKLYYKHN
KHLINNDDKNNVVNNNSYIYYDNNSNVYNNNNTNIYNNNNNNENNAFNNNMPNNSNIMNN
MNNMNDIYHISQHTNNNIRYNDVSSCGARGHNINSNENVNQNDLNNNSNYNYNRGMNNMN
GDINNINGDINNMNGDINNMNGDINNMNGDINNMNGDINNMNGGNFKNPNSYNNNNNMNS
YYSHNSSDYHKDNDNMRNNVNSSNSNFHNNNQDVQIMNRKNDSDGNVGNFDNNSTYSYMN
NVNNDISMRLTNINNNNNININNNNNNNNNLFAYNKNNPNALVNNMNNQDKPDQHNNSHQ
YMYKENDMNQFGNSNYNNMDNTNNKFYNNYNYGKNVEGHTIYDNNNNNNNNSNNGAVNIN
SVQGENNVMSRNNILFNHNVNNNEYYFSQKNEDNMASMNNNHHNNYHNNNNNHHNNNINN
HHNNNINNHHNMNRNNNIYSEDSKTNECYSMREKMGDVNVAYNSNFYDDKNNYTHMKNDL
IKNEQKNNYGFCNNHENTFIYNCKNRMNRNNYAFNMGSKKNKKIMLLKVCLSNIISINKL
LYFITRPEFLFIDNLYSIFKDYIKNRNEYNKERLSKSDYYYEQREKLYKEHRRKMNRQNI
RTDSSNNNNNNNINSNNNNNNNNNNNNNNNNNNNNNIYNNNNYYYSSSINKVSFDDDEKI
EVESFLDHNGVVGSNKKIKREKIREYFKKEKNLLKKLNFMTKFSKNTIKKSMIVMNNSDE
CIEKKKLSFSLTLLTEFDDVILIKIIDDLLNYYEKYKSKINLNEFMYFLFNIYLNICTLT
KRIINHFIDFIFSFIKKITQTSQNIMSSLWFLYILFIIENNHIYVFNDKLQKKIIVEQIS
ILIQISLYSYYSKNVKNNYNIQTPLPNFVQPFNIYYIIQNYFINNNYFHIKKNNKNIRYF
YIKNLKLIEKNFNINDYSEIAAINALSFLLMCFYHTVNYNGTNKSYICESSVNIFYEHFS
KYISLIYNNSLQNIFYRYVFLLIMNLLIDYNANSKYYIKKITFDLYSYITNVDIRCIKAL
STLFKKLNETNIDELLLVPTSSIFSLKFNIINSRINYINKLSLIILAGNRNFYLCHLPKI
AENISEYIKFCNDLKLYREILILICIIIIKNDENEIYIIIPTFISLILQIYHVERIKYKM
AVENINNIDKDDDNYIYDFNSYNNKDVLSLLKTLLIIINILIKRNVSFINFYSWIFFKDI
SIKKNRLEQQNREPGNLMIYPGHKTLVYNNKKKKQKNVVRYVSSSSDKDESSVYNISVDE
ENSLKTQGRFFDDTYYKRKDNSGYTNKMKNFNSLTYEDKSSLMTGNQTSSTKDVGGMVNN
AIRQNIEQNNMIHPNQINNNNNNNNNNNNVYNFNDFTNSMNQPNVINNNKKKKAFTTDDY
FVKYDENQKVTKQTKLNHHNEDNLNDTITVYLNSNQEDYLYESKNNFTSIRSEHISSMVD
IKKGSILNSNNILTNDNNTNNNIHSNIHNGSSSNNNNNNNSVCTGIKLDESKFVPFLDII
ERIYSPNNILNKKYVSSEELKNEKSTRTYNSSLQEGSDYDEEEDEEYDVDADVDVDVDVD
DDDDDDVDIVDVDVDDVVVDYNYYDNENNSVKIIDVDERKRSVHFYPQHLDGNTLKKNLY
YNDNYLREYILSTKNELSGYSSFENNLSSSSVNSIKSNFSNTFSKDNINKNIITDDTSDD
NDMMNSNNNMNSMMVPYNMHMTDDEFQENINNNNNNNNNNNDNMYLSSDDGYPSQSNHKW
IHFNSLLNYDIHELSKKKKKKKKKISIHSCKNLPLVLVYLSKKIKLNFYKYSMKKPKEET
IILLKELNSVENDINDLFLEVDLNEVYYDFLIR
ENDING
ENDING
ENDING
Circumsporozoite protein
MMRKLAILSVSSFLFVEALFQEYQCYGSSSNTRVLNELNYDNAGTNLYNELEMNYYGKQE
NWYSLKKNSRSLGENDDGNNEDNEKLRKPKHKKLKQPADGNPDPNANPNVDPNANPNVDP
NANPNVDPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANP
NANPNANPNANPNANPNVDPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANP
NANPNANPNANPNANPNANPNANPNANPNANPNKNNQGNGQGHNMPNDPNRNVDENANAN
SAVKNNNNEEPSDKHIKEYLNKIQNSLSTEWSPCSVTCGNGIQVRIKPGSANKPKDELDY
ANDIEKKICKMEKCSSVFNVVNSSIGLIMVLSFLFLN
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
101 kDa malaria antigen
MMNMKIVLFSLLLFVIRWNIISCNKNDKNQGVDMNVLNNYENLFKFVKCEYCNEHTYVKG
KKAPSDPQCADIKEECKELLKEKQYTDSVTYLMDGFKSANNSANNGKKNNAEEMKNLVNF
LQSHKKLIKALKKNIESIQNKKHLIYKNKSYNPLLLSCVKKMNMLKENVDYIQKNQNLFK
ELMNQKATYSFVNTKKKIISLKSQGHKKETSQNQNENNDNQKYQEVNDEDDVNDEEDTND
DEDTNDEEDTNDDEDTNDDEDTNDEEDTNDEEDHENNNATAYELGIVPVNDVLNVNMKNM
ITGNNFMDVVKNTLAQSGGLGSNDLINFLNQGKEIGENLLNITKMNLGDKNNLESFPLDE
LNMLKDNLINYEFILDNLKTSVLNKLKDLLLRLLYKAYVSYKKRKAQEKGLPEPTVTNEE
YVEELKKGILDMGIKLLFSKVKSLLKKLKNKIFPKKKEDNQAVDTKSMEEPKVKAQPALR
GVEPTEDSNIMNSINNVMDEIDFFEKELIENNNTPNVVPPTQSKKKNKNETVSGMDENFD
NHPENYFKEEYYYDENDDMEVKVKKIGVTLKKFEPLKNGNVSETIKLIHLGNKDKKHIEA
INNDIQIIKQELQAIYNELMNYTNGNKNIQQIFQQNILENDVLNQETEEEMEKQVEAITK
QIEAEVDALAPKNKEEEEKEKEKEKEKEEKEKEEKEKEEKEKEKEEKEKEKEEKEEEKKE
KEEEQEEEEEEIVPENLTTEESK
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Circumsporozoite protein
MMRKLAILSVSSFLFVEALFQEYQCYGSSSNTRVLNELNYDNAGTNLYNELEMNYYGKQE
NWYSLKKNSRSLGENDDGDNDNGNNNNGNNNNGDNGREGKDEDKRDGNNEDNEKLRKPKH
KKLKQPGDGNPDPNANPNVDPNANPNVDPNANPNANPNANPNANPNANPNANPNANPNAN
PNANPNANPNANPNANPNANPNANPNANPNVDPNANPNANPNANPNANPNANPNANPNAN
PNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNAN
PNANPNANPNANPNANPNKNNQGNGQGHNMPNDPNRNVDENANANNAVKNNNNEEPSDKH
IEQYLKKIQNSLSTEWSPCSVTCGNGIQVRIKPGSADKPKDQLDYENDIEKKICKMEKCS
SVFNVVNSSIGLIMVLSFLFLN
ENDING
ENDING
ENDING
Circumsporozoite protein
MMRKLAILSVSSFLFVEALFQEYQCYGSSSNTRVLNELNYDNAGTNLYNELEMNYYGKQE
NWYSLKKNSRSLGENDDGNNNNGDNNREGKDEDKRDGNNEDNETLRKPKHKKLKQPGDGN
PDPNANPNVDPNANPNVDPNANPNVDPNANPNANPNANPNANPNANPNANPNANPNANPN
ANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPN
ANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPN
KNNQGNGQGHNMPNDPNRNVDENANANNAVKNNNNEEPSDKHIEQYLKKIQNSLSTEWSP
CSVTCGNGIQVRIKPGSANKPKDELDYENDIEKKICKMEKCSSVFNVVNSSIGLIMVLSF
LFLN
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
RING finger protein PFF0165c
MSNKKRSKNENDESTSLPLENSELLIEYIHNLKSCLNVYRREIQEKNKYISIIKNDLSFH
ECILTNVNVVWSVFNNDLLNLLCNNEQKEEGEEIIKQRNIGDEINEYNNLTKLQNDENIK
NNNMIKEDLEDDANQNILMKSPYYNIENFLQVFLKYINKKKKKVKVKVKDEGKKEKIEDK
KYEQDDEEENEEEEEEEEEEEGEEENKEDEEFFKTFVSFNLYHNNNEKNISYDKNLVKQE
NDNKDEARGNDNMCGNYDIHNERGEMLDKGKSYSGDEKINTSDNAKSCSGDEKVITSDNG
KSYDYVKNESEEQEEKENMLNNKKRSLECNPNEAKKICFSLEEKIGTVQSVKLKEYNELS
KENIEKNKHDDNNICNYLSHNEGENVIEREDKLFNKLNNKNYRNEEEKKKNQINFDYLKK
KIKNNQDVFEETIQKCFLINLKKTLNLINKIMYLKNVEFRKYNLDYIRKINYEKCFYYKN
YIDIKKKISELQKDNESLKIQVDRLEKKKATLIYKLNNDNIRKHILDNNIKDYQNGIDNS
KVSYFDEGENPYNRNNKNYRTDNKNSDDNNNNNNYYYNNYNSDDNYNSEDNEYNNGNYRF
RNNYKKDSLNEDDVKKNPLKVCHKINSDSNIFVNFENIITKQNIIHSEPFRNLLKESNEL
YITLKEKEKENIILKNEILKMENKKDEEYEHLLNNTIEDKKELTRSIKELEINMMTCNME
KDKISNKVNTLEYEINVLKNIDKNQTMQLQQKENDILKMKLYIEKLKLSEKNLKDKIILL
ENEKDKMLSGIHIKDNSFNEESKSEEGKIQLRDIQNDNDEKYDDEKKRFKELFIENQKLK
EELNKKRNVEEELHSLRKNYNIINEEIEEITKEFEKKQEQVDEMILQIKNKELELLDKFN
NKMNKAYVEEKLKELKNTYEEKMKHINNIYKKHDDFVNIYLNLFFQARKNAILSDSQREE
QMNLFIKLKDKYDIIFQKKIELTDILKNVYDCNKKLIGHCQDLEKENSTLQNKLSNEIKN
SKMLSKNLSKNSDDHLLIEENNELRRRLICSVCMENFRNYIIIKCGHIYCNNCIFNNLKT
RNRKCPQCKVPFDKKDLQKIFLD
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Circumsporozoite protein
MMRKLAILSVSSFLFVEALFQEYQCYGSSSNTRVLNELNYDNAGTNLYNELEMNYYGKQE
NWYSLKKNSRSLGENDDGNNNNGDNGREGKDEDKRDGNNEDNEKLRKPKHKKLKQPGDGN
PDPNANPNVDPNANPNVDPNANPNVDPNANPNANPNANPNANPNANPNANPNANPNANPN
ANPNANPNANPNANPNANPNANPNANPNVDPNANPNANPNANPNANPNANPNANPNANPN
ANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNKNNQGNGQGHNM
PNDPNRNVDENANANNAVKNNNNEEPSDKHIEQYLKKIKNSISTEWSPCSVTCGNGIQVR
IKPGSANKPKDELDYENDIEKKICKMEKCSSVFNVVNSSIGLIMVLSFLFLN
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Knob-associated histidine-rich protein
MKSFKNKNTLRRKKAFPVFTKILLVSFLVWVLKCSNNCNNGNGSGDSFDFRNKRTLAQKQ
HEHHHHHHHHHHHQHQAPHQAPHQAHHHHHHGEVNHQAPQVHQQVHGQDQAHHHHHHHHH
HLHPQQPQGTVANPPSNEPVVKTQVFREARPGGGFKAYEEKYESKHYKLKENVVDGKKDC
DEKYEAANYAFSEECPYTVNDYSQENGPNIFALRKRFPLGMNDEDEEGKEALAIKDKLPG
GLDEYQNQLYGICNETCTTCGPAAIDYVPADAPNGYAYGGSAHDGSHGNLRGHDNKGSEG
YGYEAPYNPGFNGAPGSNGMQNYVHPWSGYSAPYGVPHGAAHGSRYSSFSSVNKYGKHGD
EKHHSSKKHEGNDGEGEKKKKSKKHKDHDGEKKKSKKHKDNEDAESVKSKKHKSHDCEKK
KSKKHKDNEDAESVKSKKVLKKREKSIMEKNHAAKKLTKKIKIKKKTNNSKSDGSKAHEK
KENETKNTAGENKKVDSTSADNKSTNAATPGAKDKTQGGKTDKTGASTNAATNKGQCAAE
GATKGATKEASTSKEATKEASTSKEATKEASTSKEATKEASTSKGATKEASTTEGATKGA
STTAGSTTGATTGANAVQSKDETADKNAANNGEQVMSRGQAQLQEAGKKKKKRGCCG
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Uncharacterized protein PF11_0207
MAKKKKQIHLNIIDFQKYYQTDDLLLDTSISTEKKTVDNQKFIRKNRTLEKDEVVQNIDW
RTFDNEKEKETNNENTSNVNKIKSPGLEKKNFKKSNDVITLGARNKNKSTNLNADDIDFT
NLRNKKKEDDIDFTNLRNKKKEDDLDFSNLRNKKKEEEDVDFSNLRNKKKEDDVDFSNVR
NKKKEDDLDFSNVRNKKKEDDVNFSDVRNKKKEDDLDFSNVRNKKKEDDVNFSDVRNKKK
EDDLDFSNVRNKKKEDDVNFSDVRNKKKEDALDFSNVRNKKKEDDLDFSNVRNKNKEDDM
DFSNVRNKKKEDDLDFSNVRNKKKEDDLDFSNVRNKKKEDDLNFSNVRNKKKEDDLDFSN
VRNKNKEDDMDFSNVRNKKKEDDMDFSNVRNKKKEDDLDFSNVRNKKKEDDLDFSNVRNK
KKEDDLDFSNLRNKKKEESKENDTNKSEKPLYLRRLEEYRKKKKLESQANDTAMKMHEKE
QIDDIQERKEEIKEEFKEEVKEEIKEIKEEIKEVKEEIKEEIKEEIKEVKEEIKEEIKEE
IKEVKEEIKEVKEEIKEVKEEIKEVKEEIKEEIKEVKEEIKEEIKEEIKEVKEEIKEEVK
EEIKEVKEEIKEVKEEIKEEVKEEIKEVKEEIKEVKEEIKEEIKEVKEEIKEEVKEEIKE
EIKEIKEELKNDISSETTKEEKNTEHKKEETEKKKFIPKRVIMYQQELKEKEERNLKLLE
QQRKEREMRLQLIRSKTQGTSSTFIPSAKLKHLESLKEEKKKEVKTNIQPKDNNNNNNNN
NNNNNNIAVLKNNKNEEQNVIKKKSIFLEIAEKTENAKIVEKTDIEEIAKKKREELYKKQ
LEKITKKNEEHLKYNNIYKHDVNIIKNFYNEIKDKIIQNYYFNQDDCISLCSILKTDDCN
YMESHVPFYVVISIFMLSLPQKLQNDDYFKRASNIKNLLIYLKENSKIENHEDYILNDTL
KFCDQLKYPHLSEETSLIETIFDTLLYSGVISKNSFIQWFQDDDSNAELKSKAMLQLIYW
HKWLTEEEKDQEEEIDELDDTEEKNISDVSDIEKNVPKNFIFKKIKKKLF
ENDING
ENDING
Uncharacterized protein MAL13P1.304
MNNNNNNNNNSNNNNNSNNNNNGNSNNNFFSGKGNALSAYQNKILNIKSNNNNAHHFVNK
NVPTYSPPNIIMANKKGGNFNNTSGNIINRYNVENNNHRNTYHPSNNNTRNSVNFLNKNI
LYGNNNNNNNNNNNINITNISNNNNNINITNISNNNNNINITNISNNNKQPISSNQHPYQ
QKQSHHHNNSINYNEYMDEKNMNTSQSIFKNMTIQRNSQQFNTSDFVNNINIMNAPHINE
HSNIYKRNSLNIVNNAHIISNNMNIQSNRNSNISFPQNMNANIGGLKNSNHNLNNIEMKY
NTLNNNMNSINKNTNITNVGTLNIQMKNNPMNVNINQNNYNTDFYVNENKVNSKNKENNN
NHINIEKMNYIKSNVYLDNTLVQVNSNNNYNMDKNILNNNNNTYIINDKKNSTVNNNITN
MDNNLVPGVMSSMNIPDDIKKRKKKERKKNENIYNNRNKSSINTEEHNNNIIDVANQNSE
HFLQNNKQYGNITNIQNNNLSHDMNNYSINNSTTSDVIGIVELYKNSLSSKAVNKKKSKL
IKDVIDDNKKRNKKEKKKTIPNNDSIINDMNKNKNVELLNETQIFDNKNYDKNNDIHNNI
YNSNDNNLIHNKNNVNNDHTNIKEANNNNNRKSEHSEKNKDVHNYYYANNYQCITDEKNN
KQYILWNNRTIEVTFVWLFITKEFNENRKKYTAFLPYLKHFYPNRLKDLIEQLEKYSLLK
FNYIMHSSYNMQEEYNKNKEPNNINSNDNNNKNDDNNNNNNKNVDGNNNNNNNINSNDKE
VLMNGMLLSDKSTLNSNKQIDNTLINNINSGFNNIIKNMSIDDNTIRSIMDNIENITKGK
KKGRKKKQTLENNGDNIKEDIKSSKKDKKKDNINDNNNDNNNDNNNDNNNDNNNDNNNDN
NNDNNNNNNNNNNNNNNNNNNNHNNHNDNKNNQGDSKNEQEKKKKTRQYRKKSKITNDDN
NEKIKQDNINSNNPKNDLKNNEIICSEEKNMKEDNIPDDTHYKEKRRNTFNLFNLDEGTI
NMDLFNLSLLENDDALNKKENDMVSKSNIPSSFSSPPKETNNKNDIDKEQSDKHNNVQEF
QNLNMNNEKSKDLYFNKNDIDNNDNKDKIINETSSGTFMQNLKETFYEKTKAMFSNLLSD
TKISKDDELNNEVDQNCVKTSSGILNKEENNKKEDDEKHFDDNTNEQKKNVDNGEYNEMT
AEPGRKKRKKDVLERKKKNLNKEIIKSEKRIRKYRTKKMLLKEAMEKGISNNIVESNITA
NNNNDNNKNNDNDNNNNNNDNIINNNNNNGDMFSNSYDNSYIKENKYNKKLCFPQNNLLS
DFRSEPIIIQQDKRKIIKINTINKIKRKYKKFRFCINKVFKKKSINDIIALNENIHKNKD
LLTLFKKKDLANLKKKNLSFFMDTLKLEKIDMLIMKRIQMCLEKIKNTLLLTCTINNVQE
IVNILKKAFEKRLYLMWPLIEFSNKYRLDQYFHLLGKNKNHINSSFKDTKLFVHQNISSL
ILYFNQRSMDDKWVEYLKSQMKPKRRRRKTKMKEQFLEDKPIDYLNTMNSQHSNNFIGEN
FSEIETVESKANEYAFVGYNQKRLLTQITPYDYRVVLNSNFCNKFFTPNWREQQSIFIDN
LHFDMVPDTDEIKKHFENVYIRYMEYDEEKLRSKSDTKSKEHKKKDKKYKMLFKKKEGKG
KPGRKKKIKLEIENVSNEIKIKKPRKKYERVKPRKSKNAMMNEEKSGNSEKQINNVLNVT
NIENKHKSKKGRKPKESNLNNLNINEDINVAKASPDTLHRASLEFMNPNLFT
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Uncharacterized protein PFL0250w
MSYNDGSEEENDSNTYIPDEKKKKKKKNNKNAYALINEVNYSQEDEQEVIHNTNSEDETS
NRKGNGCVYSLSDQNVEDHIISLPEYLDLINNNNNNSNSYKMKKEKKKKKKKKKNQTDEE
NMKNKKDHIYQNNITNQQNDIKNDYKKINHHNMNNKKNKIFCQDDQNIFNINHTFQIHET
VQNNLIIPPSETCLASDIIQPSDTTQSNTYLNEATASQNDDNNNEDSSNEMGMFKKIFYR
IKKIIVDKKGTPITNENDVDNDMCELNVMENNMNNIHSNNNNISTHMDDVIEDESNEEVF
VINRNTDGYINTRENINVSTHVTRQMINLSELNPNDLLCNVSEYEEGQNINSLWNDNNNN
NNNNNNNFLVGSLNALHPINHNLRNENIHNDNINNTHINYDNNNSYESPIHILSFSFKNI
YNKISSYINEHITHIKEKIKKYWLERVQEANTQLNSPRPVHTRNTTNINTNININEDEND
DPSCVQILFFMGLICKFPILWIIGSIVFCITPSEHRKTKTWSLVNTFFALLSIIYFITTT
NFRLRKPTFFVILEQNVENKNTYPKGILKYNNMIHHKHIIIDQSSLHKWKDLHTNKVYKT
SENYFLNRNFLSSQKPDSNILLSDTIYKLLNRIQVTVTFGKGNIYSSDNIEKIKPFFQNL
RINMDPISYDKLTMTDEDIPDDFFGSGLRCERTYNNHNQNINEPQQNKEKEKWYLFWKEE
EINNSHNKNIYNISIPVGEIFFFKSEYNCRIAFLYPKSILYDQNDIPSNFVEIQKIIIKP
F
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Uncharacterized protein PFB0315w
MDSDKYKKFYVYNHGFTKQPFYERNLNDKGIHLKELKRLERVDEPRLYNNVDKIPNKKEI
IYNNIKSNNIQVRVNQNNNEEKKKEEANYTCVNNKYVTLKNKVHVNKYVNNSNINKIKIV
PIIKCSNYKIKNNPISHLKSNYENKFVKLSNFSNIKNGCSHKDNVINETMDQHKSEQLNN
DNIKKLLYDYCIFREDTIKTKTNISYNKMNSFKDNEENINYMDNNNIKSNSSSYCSYSNK
INQNNVNHTHLKTEFLNEKNSHTQNEQSIPLLDGLQNNHNSATKFHNNIYDNNNSLVNYK
SDKGIDLHNKMMKIETDKNGIITLEKKKHDEKYYNNIFLNPLNDNSNNVVITTCDNKESY
RNSTSDMINKIFEKMMNEKKNILKMKNFNDVIKKKITMAKEKILNSNSTINMKKVSFYNS
KDEDLFNEKENSYKYGVKRENQEDINVIKNNMKRNNINIDNNDNINIIKNDSVSKNIHIN
NKKKRDDDFPFNNSAGLLLDFDLCKRKVLEILKNVQSSKKKNKILTNHNHSSDNQNCHSS
DNQNCHSSDNQNCHSSDNQNCHSSDNQNCDSNACNKKDEEKKRKKKKIKKKNKMKNKSNN
KSKNKRETKSKKISNNNNNDNMNNQCDNMGDQRINNENMDKQNVNIQNEGNGFNNNKNNN
DLLNVYISPNMINHSLSSTCEKKNKEDNKMNDNKFLNSSSKMKIPEISTNNSNEKIVNVS
NDEMLVYHNLTVLNVKEQGGVTEESSCIKRTYFVDQFYDSYNMRNEKITDDNMQVEDIYN
VKENIKRTLKGDGHDDVKTNMLSEDNSYASGLWGNEINFISNNENCLNSYDISCDEKYIP
NEEEQDEELCSNNILVKDIEEKKMCGKLFFEEICVFRINEKNEHGHENLRKNNHNDDTHK
MYSSYENIQNINKQSTNPFCKKDEMEKSQGTNLFYDNYINSVDITKLELNKNCYQHINYE
VQNLIKKENSYAAEMNVGLVFRKYIPILINLSCNYLLIKKNEKNVITCISYTNIIDVKIV
KKSKKNKERFLFKIVYVFKKKEQKTEKNVTLLFRANLMEIFEKIKGRVDYCIIPNEDDKN
IQLQDKKKKKGKKKKELQEEKMKKKKKTQEYVDIETVYEYVIEKYKRVHVLYLGRLLQIV
EKLFKKYILKYSFHKLRIFYEYKIEMEKLKKNYIHCIYDISDKLEFLIKKKMQHYFNHII
INSYESSFINYQIKTNDMLYNLLLKEKSAYQNHLGKNYILILYKVLLSMYKKKMAIYFRS
FVYNNIKVSKKKNAFAYTLTRVNSILVLYERRIKSFIFSKLKFNYDNVSYFCFTMYKIYL
RRILFGYLRIRDNRINIKNVIEKNVYRLVKLISKISDNHKYNAFLKLQKYVYEQNEKKNK
MICDNLIYANNELCNNLDKIAIEKGINQIDCLIKFKRKECLMKYFYTLKGPQINTERFYY
CIRYCSIFSFVLNKIIQKKVQHIFFQFVLKTLQRNNKNRLTHAIKLLQVLVQKKEKKSVI
DVLQLYDKYPYIFQYKDLTKIEVFVICVQNFVTLYNRKLLLNFLLKLHYLKYQEQFMKTY
NGIGSIYKFVHVLDKKLMNTIRESFRVILQNDKFLREKMNMKMEQMDMKMEKIDVNMDQM
DVKMEQMDVKMEQMDVKMKRMNKKKSKQIHVNYNNKAYSSSSPSPMLRYNKYKDMSSNSA
SLIKKYPFLIYNSEISPDCTTMADDKLSLPSNESVTHIFSYAYEDMDKIKKKIYDFNNKM
SNVDL
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Uncharacterized protein MAL8P1.12
MSEESFDDTNKAFENEKDIILEKIVKDENNLNNCSNMINMDDVENMKKELYVLHKKDEEI
ENNVDCFSGDKYNVENVINLKKKKKKDEDTDSSYYKTTLDEVYDTSDISTDEMLSNYSSS
EDNNNIEMNIINDFYLKDDNTYCLEWNSDIINVLSEEIKEKEKLLEDENKDICNMKSRFL
KLEKYVNIKKKKIINIKKNIEEKRKIEFDEKEIFKCLQIKNDFLKKENKKIELEREKNNK
KIIETQNNITTCQKNIDDIKKELILKENELNDFINKIKIIQQEEYEIEKIKLSKDKEIQN
VSYNLEKYNNEKIQQDKKYEQVKMNNMKFDIELKSIIQEYYDIKKDIKNISNKYICIMDM
IKCRDKTIYKFEKDYTKTIHKEKQLQNKCLHKQNLINTQKDKNIILNNQIKKIQFDINKI
RKELNDKQMSYDKTIIDRDHLNKEYEYEIVEIKEKLQEEKKSLENTLQHLNETYITMSTN
YEESKNEYEKEQVNNIEKNDLIKSSEQILVQLQNKLQKLLDEIKSLDLEKFQLTQTLQVI
KNDYITLEADVLGTQIKIKQIKSNIKKTEKELERQKEMLYKFDFQTQVLTKKINMISGIS
TFEKKKENQKKIILLEKELYKNEDIYNTLNNEMKRINIEIKNIKLYQNELQEQKMNYKNL
YEKLQLEIKSLESTINNEIKEKENIMLIELNLKIELDKLKSTFSKHVDNLNICKKEKKEN
MNNAKLSEQDINAHMESLKVIIKNINDEIHKLNIQLYEKKNKSNNLQLKLNSIIICNQKN
KDQKDICPNENQHIYYKMKIDQDIINLKEQLKKINEQIDKENIETKNFQRTLDDIIQTNK
EFNDNIKSIDPQYKILLKKKNKLNKKWEQINDHINNLETNINDYNKKIKEGDSQLNNIQL
QCENIEQKINKIKESNLKVENNINDLFIKIERASNQLKKNLAPTTNMMKLKNKQIKDDEN
NLSNNNNNNNNNNNNINVNVNVNCEPVPLEKHIFKQIQMESLKEKLSLLMECFKNNIDNV
IMKEVFNLIETAE
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Clustered-asparagine-rich protein
MNNEIVNSTIDGVLNTKLHIQNIPPHITDVHLRSLLGNVGFIKDICYFNKSKKQMNNNNF
ANKKIYNTALVTFNTHEEALNVLKNIKNLIDTSGEERNIDAKFAVPNVSINNNNNNNNSN
TFFQKNNMNNTNFSQGSTNYGSNYNSENFQGNNNMNNYNFYNNNSSNNNNNNQTNTQNNF
MNRNMKNKNMNNNNNNNNSNNNMMMNMNFNNNQQMNNNPMLNQNNFMLNNNNNYNNNAKN
VNDMYRDGEMSPNHLNNNNNNINNNNNNNNNNNNNNNVMFRQNNSHLAQMYQANDNSLED
VENVDGLSLWEMYKDKNNNIFYYNNLTKHANGINLFTQTNYSSITIMKKQNKMDLVEVTY
LFSTYLVNGQTLIYSNISVVLVILYHQKFKETVLGRNSGFGFVSYDNVISAQHAIQFMNG
YFVNNKYLKVQLKKGETVENTNS
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Circumsporozoite protein
MMRKLAILSVSSFLFVEALFQEYQCYGSSSNTRVLNELNYDNAGTNLYNELEMNYYGKQE
NWYSLKKNSRSLGENDDADNGDADNGDEGIDENRRHRNKEGKEKLKKPKHNKLKQPGNDN
VDPNANPNVDPNANPNVDPNANPNVDPNANPNVDPNANPNVNPNANPNVDPNANPNVNPN
ANPNVNPNANPNVNPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPNANPN
ANPNANPNANPNANPNANPNANPNRNNEANGQGHNKPNDQNRNVNENANANNAGRNNNNE
EPSDKHIEEFLKQIQNNLSTEWSPCSVTCGNGIQVRIKPGSAGKPKDQLDYENDLEKKIC
KMEKCSSVFNVVNSSIGLIMVLSFLFLN
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Heat shock 70 kDa protein
MASAKGSKPNLPESNIAIGIDLGTTYSCVGVWRNENVDIIANDQGNRTTPSYVAFTDTER
LIGDAAKNQVARNPENTVFDAKRLIGRKFTESSVQSDMKHWPFTVKSGVDEKPMIEVTYQ
GEKKLFHPEEISSMVLQKMKENAEAFLGKSIKNAVITVPAYFNDSQRQATKDAGTIAGLN
VMRIINEPTAAAIAYGLHKKGKGEKNILIFDLGGGTFDVSLLTIEDGIFEVKATAGDTHL
GGEDFDNRLVNFCVEDFKRKNRGKDLSKNSRALRRLRTQCERAKRTLSSSTQATIEIDSL
FEGIDYSVTVSRARFEELCIDYFRDTLIPVEKVLKDAMMDKKSVHEVVLVGGSTRIPKIQ
TLIKEFFNGKEACRSINPDEAVAYGAAVQAAILSGDQSNAVQDLLLLDVCSLSLGLETAG
GVMTKLIERNTTIPAKKSQIFTTYADNQPGVLIQVYEGERALTKDNNLLGKFHLDGIPPA
PRKVPQIEVTFDIDANGILNVTAVEKSTGKQNHITITNDKGRLSQDEIDRMVNDAEKYKA
EDEENRKRIEARNSLENYCYGVKSSLEDQKIKEKLQPAEIETCMKTITTILEWLEKNQLA
GKDEYEAKQKEAESVCAPIMSKIYQDAAGAAGGMPGGMPGGMPGGMPSGMPGGMNFPGGM
PGAGMPGNAPAGSGPTVEEVD
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Rhoptry antigen protein (Fragment)
VDILEEKTKDQDLEIELYKYMGPLKEQSKSTSAASTSDELSGSEGPSTESTSTGNQGEDK
TTDNTYKEMEELEEAEGTSNLKKGLEFYKSSLKLDQLDKEKPKKKKSKRKKKRDSSSDRI
LLEESKTFTSENEL
ENDING
ENDING
ENDING
ENDING
ENDING
ENDING
Sexual stage-specific protein
MNIRKFIPSLALMLIFFAFANLVLSDANDKAKKPAGKGSPSTLQTPGSSSGASLHAVGPN
QGGLSQGLSGKDSADKMPLETQLAIEEIKSLSNMLDKKTTVNRNLIISTAVTNMIMLIIL
SGIVGFKVKKTKNADDDKGDKDKDKDNTDEGDEGDDS
ENDING
ENDING
ENDING
Uncharacterized protein PFB0145c
MVFTFKNKKKKKEASSDKVSKESFNEEDNENNEKREKSDSWYKKIIETKGKSKTKYKNDN
SLDDNINEDIINNNNNNNNDNNNDNNNDNNNDNNNDNNNDNNNENNNDNNNFNNYSDEIS
KNIIHKDNELENQLKDTLKSISSLSNKIVNYESKIEELEKELKEVKDKNIDNNDYENKLK
EKEDFVKQKIDMLNEKENLLQEKELDINKREKKINEKEKNIIKKEETFHNIEKEYLEKNK
ERETISIEIIDIKKHLEKLKIEIKEKKEDLENLNKKLLSKENVLKELKGCVKEKNETINS
LNDNIIEKEKKYKLLEYELEEKNKQIDLLNKQEKEKEKEKEREKEKEREKEKEKEYDTLI
KELKDEKISILEKVHSIKVREMDIEKREHNFLHMEDQLKDLKNSFVKNNNQLKVYKCEIK
NLKTELEKKEKELKDIENVSKEEINKLINQLNEKEKQILAFNKNHKEEIHGLKEELKESV
KITKIETQELQEMVDIKQKELDQLQEKYNAQIESISIELSKKEKEYNQYKNTYIEEINNL
NEKLEETNKEYTNLQNNYTNEINMLNNDIHMLNGNIKTMNTQISTLKNDVHLLNEQIDKL
NNEKGTLNSKISELNVQIMDLKEEKDFLNNQIVDLSNQIDLLTRKMEEKENKMLEQENKY
KQEMELLRGNIKSSENILNNDEEVCDLKRKLSLKESEMKMMKEEHDKKLAELKDDCDVRI
REMNEKNEDKINMLKEEYEDKINTLKEQNEDKINTLKEQNEDKINTLKEEYEHKINTMKE
EYEHKINTLNEQNEHKINTLNEQNEHKINTMKEEYEDKMNTLNEQNEDKMNSLKEEYENK
INQINSNNEIKIKDVVNEYIEEVDKLKVTLDEKKKQFDKEINYAHIKAHEKEQILLTEME
ELKCQRDNKYSDLYEKYIKLIKSICMIINIECCDDIENEDIIRRIEEYINNNKGLKKEVE
EKEHKRHSSFNILKSKEKFFKNSIEDKSHELKKKHEKDLLSKDKEIEEKNKKIKELNNDI
KKLQDEILVYKKQSNAQQVDHKKKSWILLKDKSKEKIKDKENQINVEKNEEKDLKKKDDE
IRILNEELVKYKTILYNLKKDPLLQNQDLLSKIDINSLTINEGMCVDKIEEHILDYDEEI
NKSRSNLFQLKNEICSLTTEVMELNNKKNELIEENNKLNLVDQGKKKLKKDVEKQKKEIE
KLNKQLTKCNKQIDELNEEVEKLNNENIELITYSNDLNNKFDMKENNLMMKLDENEDNIK
KMKSKIDDMEKEIKYREDEKKRNLNEINNLKKKNEDMCIKYNEMNIKYGDICVKYEEMSL
TYKETSLKYEQIKVKYDEKCSQYDEIRFQYDEKCFQYDEINKKYGALLNINITNKMVDSK
VDRNNNEIISVDNKVEGIANYLKQIFELNEEIIRLKGEINKISLLYSNELNEKNSYDINM
KHIQEQLLFLEKTNKENEEKIINLTSQYSDAYKKKSDESKLCGAQFVDDVNIYGNISNNN
IRTNEYKYEEMFDTNIEEKNGMHLSKYIHLLEENKFRCMKIIYENENIKSSNKIIGLYNY
SRYYGLREDLCKEEIVPSKIGNISNKNENNNKKNNTCDGYDEKVTIVLCIILNEIIKFLF
LNDEYVLLFEKIHKNVWKRMYIPEEIKFFILKYITLLNNLRDYIISVHNNMKNEKYDECW
FLFQHYFERSSDVRKEMVHFLLERKSQENLISFKSKLKSKKEKILTMDILNFSKEHMQLK
TIAHLRKEINYEKLSKDTLNRDYNLLLYKYQECVSKLKRVKNLMKEINQNVFIEKYDDIS
KELDNFSDGYNEQNEQHVMDPILLNNNKNKNNKLITEHNNPIINRLTNFTQNRDSKYKNK
IMDDVKQRKINSTMNNTNKNGINIIYNHYENLNKPNYNDNINRLNSYHQNIHIANSIHPN
RNQNKSFLTNQANSTYSVMKNYINSDKPNLNGKKSVRNIFNEIVDENVNKTFVHKSVFF
ENDING
ENDING
